Novartis Research and Development
Sacubitril/Valsartan
Clinical Trial Protocol CLCZ696B2319E1 / [STUDY_ID_REMOVED]
A multicenter study to ev aluate long -term safety and 
tolerability of open label sacubitril/v alsartan in pediatric 
patients w ith heart failure due to sy stemic left v entricle 
systolic dy sfunction w ho hav e completed study 
CLCZ696B2319
Document type: Amended Clinical Trial Protocol
EUDRACT number: 2018 -004154 -25
Version number: 02 (clean )
Clinical trial phase: 3b
Release date: 30-Nov-2021
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis
Clinical Trial Protocol Template Version 2.0 (01 -Aug-2018)

Novartis Confidential Page 2
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Table of contents
Table of contents ................................................................................................................. 2
List of tables ........................................................................................................................ 5
List of figures ...................................................................................................................... 5
List of abbreviations ............................................................................................................ 6
Glossary  of terms ................................................................................................................. 8
Amendment 2 .................................................................................................................... 10
Amendment 1 .................................................................................................................... 11
Protocol summary .............................................................................................................. 14
1Introducti on
....................................................................................................................... 17
1.1 Background ............................................................................................................ 17
1.2 Purpose .................................................................................................................. 18
2Objectives and endpoints ................................................................................................... 18
3Study  design ...................................................................................................................... 19
4Rationale ............................................................................................................................ 22
4.1 Rationale for stud y design ................................ ................................ ..................... 22
4.2 Rationale for dose/regimen and duration of treatment .......................................... 22
4.3 Rationale for choice of control drugs .................................................................... 23
4.4 Purpose and timing of interim anal yses/design adaptations .................................. 23
4.5 Risks and benefits .................................................................................................. 23
4.6 Rationale for Public Health Emergency  mitigation procedures
............................ 24
5Population .......................................................................................................................... 24
5.1 Inclusion criteria .................................................................................................... 24
5.2 Exclusion criteria ................................................................................................... 25
6Treatment ........................................................................................................................... 26
6.1 Study  treatment ...................................................................................................... 26
6.1.1 Investigational and control drugs .......................................................... 26
6.1.2 Additional study  treatments .................................................................. 27
6.1.3 Treatment arms/group ........................................................................... 27
6.1.4 Treatment duration ................................................................................ 27
6.2 Other treatment(s) .................................................................................................. 27
6.2.1 Concomitant therap y
............................................................................. 27
6.2.2
Prohibited medication ........................................................................... 29
6.2.3
Rescue medication ................................................................................ 29
6.3 Subject numbering and treatment assignment ....................................................... 29
6.3.1 Subject numbering ................................................................................ 29

Novartis Confidential Page 3
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
6.3.2 Treatment assignment ........................................................................... 30
6.4 Treatment blinding ................................................................................................. 30
6.5
Dose escalation and dose modification.................................................................. 30
6.5.1 Dose modifications ................................................................................ 30
6.6 Additional treatment guidance ............................................................................... 32
6.6.1 Treatment compliance ........................................................................... 32
6.6.2 Emergency  breaking of assigned treatment code .................................. 32
6.7 Preparation and dispensation ................................................................................. 32
6.7.1 Handling of study  treatment and additional treatment .......................... 33
6.7.2 Instruction fo
r prescribing and taking stud y treatment ......................... 33
7Informed consent procedures ............................................................................................ 34
8
Visit schedule and assessments ......................................................................................... 35
8.1 Screening ............................................................................................................... 41
8.1.1 Information to be collected on screening failures ................................. 41
8.2
Subject demographics/other baseline characteristics............................................. 42
8.3 Efficacy .................................................................................................................. 42
8.4 Safety /Tolerability ................................................................................................. 42
8.4.1 Laboratory  evaluations .......................................................................... 43
8.4.2 Pregnancy  and assessments of fertility ................................................. 45
8.4.3 Other safety
 evaluations ........................................................................ 47
8.4.4 Appropriateness of safety  measurements .............................................. 47
8.5
Additional assessments.......................................................................................... 47
9Study  discontinuation and completion .............................................................................. 48
9.1 Discontinuation ...................................................................................................... 48
9.1.1 Discontinuation of study  treatment ....................................................... 48
9.1.2 Withdrawal of informed consent ........................................................... 48
9.1.3 Lost to follow -
up................................................................................... 49
9.1.4 Early study termination by the sponsor ................................................. 49
9.2 Study  completion and post -study  treatment .......................................................... 50
10Safety  monitoring and reporting ........................................................................................ 50
10.1 Definition of adverse events and reporting requirements ...................................... 50
10.1.1 Adverse events ...................................................................................... 50
10.1.2 Serious adverse events .......................................................................... 51
10.1.3 SAE reporting
........................................................................................ 52
10.1.4 Pregnancy  reporting .............................................................................. 53
10.1.5 Reporting of stud y treatment errors including misuse/abuse ................ 54

Novartis Confidential Page 4
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
10.2 Additional Safety  Monitoring ................................ ................................ ................ 54
10.2.1 Liver safety  monitoring ......................................................................... 54
10.2.2 Renal safet y monitoring ........................................................................ 56
10.2.3
Angioedema Adjudication committee................................................... 56
11Data collection and database management ........................................................................ 57
11.1
Data collection....................................................................................................... 57
11.2 Database management and quality  control ............................................................ 57
11.3 Site monitoring ...................................................................................................... 57
12Data analy sis and statistical methods ................................................................................ 58
12.1 Analy sis sets .......................................................................................................... 58
12.2
Subject demographics and other baseline characteristics...................................... 58
12.3 Treatments ............................................................................................................. 59
12.4 Analy sis of the primary  endpoint(s) ...................................................................... 59
12.4.1 Definition of primary  endpoint(s) ......................................................... 60
12.5 Analy sis of secondary  endpoints ........................................................................... 60
12.6 Analy sis of exploratory  endpoints ......................................................................... 60
12.7 Interim anal yses..................................................................................................... 60
12.8
Sample size calculation.......................................................................................... 60
12.8.1 Primary  endpoint(s) ............................................................................... 60
12.8.2 Secondary  endpoint(s) ........................................................................... 60
13Ethical considerations and administrative procedures ...................................................... 60
13.1 Regulatory
 and ethical compliance ........................................................................ 60
13.2 Responsibilities of the investigator and IRB/ IEC.................................................. 60
13.3 Publication of study  protocol and results ............................................................... 61
13.4 Quality  Control and Quality  Assurance ................................................................. 61
14Protocol adherence ................................ ................................ ................................ ............ 61
14.1 Protocol amendmen ts............................................................................................. 62
15References ......................................................................................................................... 63
16Appendices ................................ ................................ ................................ ........................ 64
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs ......................... 64
16.2 Appendix 2: Liver event and laboratory  trigger definitions and follow -up 
requirements .......................................................................................................... 66
16.3
Appendix 3: Specific renal alert criteria and actions ............................................. 69
16.4 Appendix 4: Guidelines for the management of renal dy sfunction ....................... 71
16.5
Appendix 5: American heart association (AHA) pediatric advanced life 
support (PALS) guidelines .................................................................................... 72
16.6 Appendix 6: Guidelines for the management of blood pressure
........................... 74

Novartis Confidential Page 5
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
16.7 Appendix 7: Treatment guidelines for elevated potassium and hy perkalemia 
(serum potassium ≥ 5.3 mmo l/L)........................................................................... 75
16.8 Appendix 8: Reference table –blood volume by  weight ...................................... 77
List of tables
Table 2
-1 Objectives and related endpoints .......................................................... 18
Table 3
-1 Safety  monitoring criteria for initiation/up -titration of st udy drug .......20
Table 3-2 Study  drug dose levels for sacubitril/valsartan ..................................... 20
Table 3
-3 Total daily dose levels of commonly prescribed ACEI /ARBs for 
the purpose of comparing to dose levels of study  drug ......................... 21
Table 6-1 Open -label sacubitril/valsartan formulations ........................................ 26
Table 6
-2 Prohibited medications.......................................................................... 29
Table 8
-1 Assessment Schedule ............................................................................ 37
Table 8
-2 Physical Assessments ............................................................................ 43
Table 8
-3 Laboratory  Assessments ........................................................................ 45
Table 10
-1 Events commonly  seen in study  population .......................................... 53
Table 10
-2 Guidance for capturing the study  treatment errors including 
misuse/abuse ......................................................................................... 54
Table 16
-1 Clinically  notable laboratory  values ...................................................... 64
Table 16
-2 Criteria for clinically  notable vital signs ............................................... 65
Table 16
-3 Liver event and laboratory  trigger definitions ...................................... 66
Table 16
-4 Follow -up requirements for li ver events and laboratory  triggers .......... 66
Table 16-5 Specific renal alert criteria and actions ................................................. 69
Table 16-6 GFR b y age for initiation/up -titration and exclusion criteria ................ 70
Table 16-7 5thpercentile systolic blood pressure (SBP) table ................................. 72
Table 16
-8 Reference table –blood collection volumes by  body  weight (kg) ........ 77
List of figures
Figure 3 -1 Study  Design ......................................................................................... 22

Novartis Confidential Page 6
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
List of abbreviations
ACEI Angiotensin Converting Enzyme (inhibitor)
AE Adverse Event
Alb Albumin
ALP Alkaline Phosphatase
ALT Alanine Aminotransferase
ARB Angiotensin Receptor Blocker
ARNI Angiotensin Receptor Neprilysin Inhibitor 
AST Aspartate Aminotransferase
AT1 Angiotensin Type 1
bid bis in die/twice a day
BUN Blood Urea Nitrogen
CCB Calcium Channel Blocker
CHBP Child Bearing Potential Females
CHF Chronic Heart Failure
CMO Chief Medical Office
CMV Cytomegalovirus
CRA Clinical Research Associate
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CTT Clinical Trial Team
CV Cardiovascular
DAR Dosage Administration Record
DBP Diastolic Blood Pressure
EBV Epstein -Barr virus
EDC Electronic Data Capture
eGFR Estimated Glomerular Filtration Rate
EMA
EoSEuropean Medicines Agency
End of Study
eSource Electronic Source
EU European Union
FDA Food and Drug Administration
FPFV First Patient First Visit
FSH Follicle Stimulating Hormone
GCP Good Clinical Practice
GGT Gamma -glutamyl transferase
HF Heart Failure
HFrEF HF with R educed Ejection Fraction
HSV Herpes Simplex Virus
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council forHarmoni zation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IN Investigator Notification
INR International Normalized Ratio

Novartis Confidential Page 7
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
IRB Institutional Review Board
IRT Interactive Response Technology
IUD Intrauterine Device
LFT Liver function test 
LPLV Last Patient Last Visit
MedDRA Medical Dictionary for Regulatory Activities 
MRP2 Multidrug resistance protein 2
NEP Neprilysin
NSAID Non-steroidal Anti -Inflammatory Drug
PD Pharmacodynamic(s)
PK Pharmacokinetic(s)
PS Patient Safety
PSD Premature Subject Discontinuation
PT Prothrombin Time
OLE Open Label Extension
QMS Quality Management System
RBC Red Blood Cell(S)
RoW  Rest of World
RRR Relative Risk Reduction
R Value ALT/ALP ×ULN
SAE Serious Adverse Event
SAF Safety Set
SBP Systolic Blood Pressure
SGOT Serum Glutamic Oxaloacetic Transaminase
SGPT Serum Glutamic Pyruvic Transaminase
SOPs Standard Operating Procedures
STD Study Treatment Discontinuation
SUSAR Suspected Unexpected Serious Adverse Reaction
TBL Total Bilirubin
TEAE Treatment -Emergent Adverse Event
ULN Upper Limit of Normal
USM
UTIUrgent safety measure 
Urinary Tract Infection 
WBC White Blood Cell(S)
WHO World Health Organization
WoC Withdrawal of Consent

Novartis Confidential Page 8
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Glossary  of terms
Additional treatment Medicinal products that may be used during the clinical trial as described in the 
protocol, but not as an investigational medicinal product (e.g. any background 
therapy)
Assessment A procedure used to generate data required by the study
Biologic alSamples A biological specimen including, for example, blood (plasma, serum), saliva, tissue, 
urine, stool, etc. taken from a study subject 
Cohort A specific group of subjects fulfilling certain criteria and generally treated at the 
same time
Control drug A study drug (active or placebo) used as a comparator to reduce assessment bias, 
preserve blinding of investigational drug, assess internal study vali dity, and/or 
evaluate comparative effects of the investigational drug
Dosage Dose of the study treatment given to the subject in a time unit (e.g. 100 mg once a 
day, 75 mg twice a day)
Electronic Data 
Capture (EDC)Electronic data capture (EDC) is the electronic acquisition of clinical study data 
using data collection systems, such as W eb-based applications, interactive voice 
response systems and clinical laboratory interfaces. EDC includes the use of 
Electronic Case Report Forms (eCRFs) which are used to capture data transcribed 
from paper source forms used at the point of care
End of the clinical trial The end of the clinical trial is defined as the last visit of the last subject or at a later 
point in time as defined by the protocol
Enrollment Point/time of subject entry into the study at which informed consent must be 
obtained 
Investigational drug/
treatmentThe drug whose properties are being tested in the study
Medication number A unique identifier on the label of medication kits
Other tr eatment Treatment that may be needed/allowed during the conduct of the study (i.e. 
concomitant or rescue therapy)
Part A sub -division of a study used to evaluate specific objectives or contain different 
populations. For example, one study could contain a single dose part and a multiple 
dose part, or a part in subjects with established disease and in those with newly -
diagnosed disease
Patient An individual with the condition of interest for the study
Period The subdivisions of the trial design (e. g. Screening, Treatment, Follow -up) which are 
described in the Protocol. Periods define the study phases and will be used in 
clinical trial database setup and eventually in analysis
Personal data Subject information collected by the investigator that is transferred to Novartis for the 
purpose of the clinical trial. This data includes subject identifier information, study 
information and biological samples. 
Premature subject 
withdrawalPoint/time when the subject exits from the study prior to the planned com pletion of 
all study drug administration and/or assessments; at this time all study drug 
administration is discontinued and no further assessments are planned
Randomization number A unique identifier assigned to each randomized subject
Screen Failure A subject who did not meet one or more criteria that were required for participation 
in the study
Source Data/Document Source data refers to the initial record, document, or primary location from where 
data comes. The data source can be a database, a datase t, a spreadsheet or even 
hard-coded data, such as paper or an electronic source ( eSource ).
Start of the clinical trial The start of the clinical trial is defined as the signature of the informed consent by 
the first subject

Novartis Confidential Page 9
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Study treatment Any single drug or combination of drugs or intervention administered to the subject 
as part of the required study procedures
Study treatment 
discontinuationWhen the subject permanently stops taking any of the study drug(s) prior to the 
defined study treatment completion date (if any) for any reason; may or may not also 
be the point/time of study discontinuation 
Subject A trial participant (can be a healthy volunteer or a patient)
Subject number A unique number assigned to each subject upon signing the informed consent. This 
number is the definitive, unique identifier for the subject and should be used to 
identify the subject throughout the study for all dat a collected, sample labels, etc.
Treatment arm/group A treatment arm/group defines the dose and regimen or the combination, and may 
consist of 1 or more cohorts.
Variable A measured value or assessed response that is determined from specific 
assessments and used in data analysis to evaluate the drug being tested in the 
study
Withdrawal of study 
consent ( WoC)Withdrawal of consent from the study occurs only when a subject does not want to 
participate in the study any longer and does not allow any further collection of 
personal data 

Novartis Confidential Page 10
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Amendment 2
Amendment rationale 
This is the second amendment to the protocol. 
On 26-Oct- 2021, an urgent safet y measure (USM) was implemented by Novartis in the 
PANORAMA -HF study  (CLCZ696B2319). 
As a result, not all the patients were on study drug treatment at PANORAMA- HF Part 2 End of 
Study  visit (Visit 416). The purpose of the second protocol amendment is to amend the inclusion 
and exclusion criteria to allow patients impacted by the USM to enroll into this open -label 
extension (OL E) stud y.
Changes to the protocol
The following changes have been implemented in the protocol and protocol summary : 
1.Section 5.1 Inclusion criteria#2: Patient was on study  medication at the PANORAMA -HF 
Part 2 End of Study  visit (Visit 416) or discontinued study  drug treatment early due to the 
implementation of the USM and does not have any significant safet y issue as determined 
by the investigator.  Based on the investigator judgement, the patient is able to safely enroll 
in the OL E study .
2.Section 5.2 Exclusion criteria#1: Patient who only participated in Part 1 of the 
PANORAMA -HF study  or was a screen failure in PANORAMA -HF or permanently  
discontinued study  drug in Part 2 of the PANOR AMA -HF stud y for reasons other than the 
implementation of the USM.
3.Section 3, Section 5 and Table 8 -1were updated accordingl y.
4.Section 8.1clarifi edthat t he use complete lab results from Visit 416 of PANORAMA- HF 
for Visit 500 screening assessment would not be applicable to patients who discontinued 
study  drug treatment early  due to the implementation of the USM. 
5.Section 10.1.3 updated SAE reporting language per recent Health Authority Requirement 
in German y. 
6.Updates have been made to the L ist of abbreviations. 
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities, if applicable.

Novartis Confidential Page 11
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Amendment 1
Amendment rationale 
This is the first amendment to the protocol. The primary  purpose of the current protocol 
amendment is to extend the duration of the study .The current duration of the original protocol 
is expected to end as early as May-2022 and no later than Dec-2022. In this amendment the 
duration of the study  is extended to ensure that study  patients continue to receive age-
appropriate study  drug treatment (especiall y those requiring the pediatric formulations not 
currentl y available outside investigational use) and safety  follow -up until the expected time 
when pediatric use of sacubitril/valsartan receives local marketing authorization and becomes 
commerciall y available to patients. 
First patient first visit of this open -label extension (OLE) study  occurred on 02 -May-2019. As 
of 31-Jul-2021, 17 8 patients have been screened and 173 patients have been enrolled into this 
study .
Major changes to the protocol
The following changes have been implemented throughout the protocol: 
Theduration of the study  isextended to 2 years from last patient last visit (LPLV) of 
part 2 of the PANORAMA -HFcore study  (i.e., until approximately  Dec-2023), receipt 
of local marketing authorization and commercial availability, or reaching the maximum 
limit allowed by local regulations, whichever occurs first (Section 4.2, Section 6.1.4, 
Table 8
-1, and other places of the protocol) .
In countries where the sacubitril/valsartan isalready authorized for pediatric use(e.g., 
the United States) , patients may participate in the study  for up to 1 year before being 
transitioned to commercially  available product. If the formulation the patient is taking 
is not yet commerciall y available at the end of 1 year, the patient may continue in the 
study  until the formulation becomes commerciall y available or until the maximum limit 
allowed by local regulations or until Dec- 2023, whichever occurs first (Section 4.2, 
Section 6.1.4, and other places of the protocol)
Clarification was added that the study may also be terminated prematurel y if the results 
of the core stu dy does not support local 
registration ( Section 9.1.4).
Other changes to the protocol are:
The purpose of this study  was updated by adding“to provide post-trial access to 
sacubitril/valsartan to eligible CL
CZ696B2319 (PANORAMA -HF) patients” ( Section 
1.2).
The phase of the study  has been corrected from “2b” to “3” in protocol summary and 
Section 3.
A 30-day window from the PANORAMA -HF core study  Visit 416 [End of study  
(EOS) ]to the initiation of study  treatment of this OLE study  (Visit 501) was defined to 
ensure minimal change in health status of these patients roll-over to the OLEstudy 
(Section 3 and Section 8.1 ).

Novartis Confidential Page 12
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Study  design Figure 3-1was updated to clarify  that there is no additional up-titration 
step after Dose level 4. Additional visit schedules were added to reflect change of the 
duration of the study .
Maximum study  duration for patients in Germany  was updated to 4 ( Section 4.2 ) .
Section 4.6 was added to include the disruption proofing aspects with respect to study 
procedures in case of a public health emergency per new Novartis guidelines. Section 7
and Section 8 included this change accordingl y.
Clarification that the complete laboratory assessment at screening (Visit 500) should be 
conducted to assess eligibility . To reduce the burden to the patients, when Visit 500 is 
conducted within 14 days from the core study  Visit 416 and when Visit 416 laboratory 
results are available at the time of Visit 500, Visit 416 laboratory assessments can be 
used to evaluate the OLE screening criteria instead of obtaining additional screening 
laboratory  assessments at Visit 500 (Section 8.1 and Table 8-1).
Clarification that Visit 501 is the visit for first drug administration. Abbreviated local 
lab may  be performed at Visit 501 per the investigator’s clinical judgement (e.g., if it is 
believed that the patient’s health status may have changed since the screening visit
labo
ratory  tests were performed) ( Section 8.1 and Table 8-1).
Clarification that the baseline laboratory  assessments is the complete lab performed at 
screening (Visit 500), not the abbrev iated lab performed at Visit 501 ( Table 8-1and 
other places of the protocol).
Considering the rapid growth in pediatric patients, additional height measurements at 6
-
month intervals will be recorded in the source document s (Table 8-1). Statement was 
addedforstanding height measurement using a stadiometer in stocking feet ( Table 8-2).
Clarification that if the study  drug treatment is permanentl y discontinued, the patient 
should be discontinued from the entire study (Section 6.5.1 and Section 9.1.1). 
InSection 
10.2.2 the guida nce statements for renal safet y monitoring were removed
since therenal safet y monitoring guidance detailed in Appendix 3are considered 
sufficient for the purposes of this study .
Clarification was added i n Appendix 3that the most recentl y available height should be 
used for eGFR calculation. The modified Schwartz formula was added for calculation 
of estimated glomerular filtration rate (eGFR) for patients < 18 y ears of age.
Table 16-2 criteria for clinically  notable vital signs for age groups less than 1 year,which 
is not applicable to this study ,was removed.
Miscellaneous changes were made to clarify  some study  procedures and details, to 
remove redundant text, and to correct typographical errors, and inconsistencies in the 
protocol.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using 
strike through red font for deletions and red underlined for insertions.
IRBs/IECs

Novartis Confidential Page 13
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities, if applicable.
The changes herein are also reflected in the Informed Consent.

Novartis Confidential Page 14
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Protocol summary
Protocol CLCZ696B2319E1
Full TitleA multicenter study to evaluate long- term safety  and tolerability of open -label 
sacubitril/valsartan in pediatric patients with heart failure due to s ystemic left 
ventricle s ystolic dysfunction who have completed study CLCZ696B2319
Brief Title CLCZ696B2319E1 open -label extension (OLE) study  to evaluate long -term 
safety and tolerability of sacubitril/valsartan in pediatric patients with heart 
failure
Sponsor and 
Clinical PhaseNovart is; Phase 3b
Investigation type Drug
Study type Interventional
Purpose and 
rationaleThe purpose of this study is to evaluate long-term safety and tolerability data
and to provide post- trial access to sacubitril/valsartan to eligible 
CLCZ696B2319 ( PANORAMA -HF)patients receiving open -label 
sacubitril/valsartan .The rationale of providing post -trial access is to provide 
uninterrupted access to the study medication to patients until the medication 
can be obtained commercially.
Primary 
Objective(s)The primary  objective is to evaluate safety and tolerability of
sacubitril/valsartan in eligible PANORAMA -HF subjects receiving open -label 
sacubitril/valsartan .
Secondary 
ObjectivesThere are no secondar y objectives for this study
Study design This trial is a multicenter, open- label long -term study for subjects who have 
successfully completed Part 2 of the PANORAMA -HF trial. Subjects who 
successfully completed the 52- week randomized double -blind, treatment 
period of PANORAMA -HF (i.e. on dose level 1 or hi gher at the PANORAMA -
HF End of Study visit) and are eligible for the Open -Label Extension ( OLE)or 
who discontinued study drug treatment early in Part 2 due to the 
implem entation of USM of PANORAMA -HF,according to the protocol and in 
the opinion of the in vestigator, will be offered the option to initiate treatment 
with sacubitril/valsartan by enrolling into this study (CLCZ696B2319E1). For 
all consenting subjects eligibility for the OLE will be assessed at the 
Screening visit (Visit 500). During the study, visits to assess safety will be 
conducted at Visit 501 and at 3 -month intervals until the conclusion of the 
study (except for Visits 502, 503, 504 and 505 for the up -titration steps, which 
are at 2 -week intervals). 
Population Study population consists of pediatric Heart Failure ( HF)patients ≥ 13 
months, in -patients or outpatients. Subjects will be divided into two age 
groups (Age Group 1: 6 years and older; Age Group 2: 1 to < 6 years old).All 
patients who safely tolerated study  drug in PANORAMA -HF, as defined by 
the Inclusion/Exclusion criteria for the OLE, can be considered for eligibility in 
this open -label study.
Key Inclusion 
criteriaSigned informed consent as well as assent at an appropriate age 
based on country regulations must be obtained prior to participation 
in the study .

Novartis Confidential Page 15
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Patient was on study medication at the PANORAMA -HF Part 2 End 
of Study visit (Visit 416) or discontinued study drug treatment early 
due to the implementation of the urgent safety measure (USM) and 
does not have any significant safety issue as determined by the 
investigator. Based on the investigator judgement, the patient is able 
to safely enroll in the OLE study.
Key Exclusion 
criteri aPatient who only participated in Part 1 of the PANORAMA -HF study 
or was a screen failure in PANORAMA -HF or permanently 
discontinued study drug in Part 2 of the PANORMA -HF study for 
reasons other than the implementation of the USM .
Use of investigational drugs within 5 half -lives of enrollment or within 
30 days whichever is longer; or longer if required by local regulations 
–with the exception of PANORAMA –HF study  drug. For 
PANORAMA -HF study drug (sacubitril/valsartan/placebo; 
enalapril/placebo), a minimum of 36 -hour washout period is required 
before the initiation of study medication visit ( Visit 501).
History of hypersensitivity or allergy to any of the stud y treatments or 
its excipients or to drugs of similar chemical classes, Angiotensin 
Converting Enzy me (inhibitor) ( ACEIs ), Angiotensin Receptor 
Blockers ( ARBs ), or Neprilysin ( NEP)inhibitors as well as known or 
suspected contraindications to sacubitril/va lsartan.
Renal vascular hypertension (including renal arter y stenosis).
Patients with significant renal estimated glomerular filtration rate 
(eGFR calculated using the modified Schwartz formula < 30% mean 
GFR for age, Appendix 3 , Table 16-6); hepatic (serum aspartate 
aminotransferase or alanine aminotransferase > 3 times upper limit 
of normal); gastrointestinal or biliary disorders (that could impair 
absorption, metabolism, or excre
tion of orally administered 
medications).
Patients with a history of angioedema.
Patients who have parents or legal guardians who do not give 
consent or allow the child to give assent, or inability of the patient or 
the parents/legal guardians to follow instructions or comply  with 
follow -up procedures.
Any medical condition(s) that may  put the patient at risk in the 
investigator’s opinion, or that the investigator deems unsuitable for 
the study.
Study treatment Sacubitril/valsartan
Efficacy 
assessmentsThere will be no efficacy  assessments in this study.
Key safety 
assessmentsAdverse Events ( AEs), Serious Adverse Events ( SAEs ), laborator y values, 
vital signs, and duration of exposure
Data analysis The primary  safety assessment will be based on adverse events, which will 
be analyzed using frequencies and percentages. Summary  statistics will be 
provided for each age group and overall for demographics and baseline 
characteristics, including age, age gr oup (only for overall), sex, race, 
ethnicity, weight, height, vital signs. Continuous variables will be summarized 
using n, mean, standard deviation, median, minimum, and maximum. 
Categorical variables will be summarized using frequencies and percentages. 
Relevant medical histories will be summarized, by system organ class and 

Novartis Confidential Page 16
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
preferred term, for overall and for each age group. The Safety Set ( SAF)will 
be used for the above analyses.
Key words Pediatric, LCZ696, sacubitril/valsartan, heart failure, open -label study,
angiotensin receptor neprilysin inhibitor (ARNI)

Novartis Confidential Page 17
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
1 Introduction
1.1 Background
Pediatric heart failure (HF) is characterized by significant morbidity  and mortality , frequent 
hospitalization and medical care, and poor qualit y of life. It is estimated that between 12,000 to 
35,000 children below age 19 are diagnosed with HF in the United States (US) each year ( Hsu 
and Pearson 2009). Congenital heart disease and cardiomy opathy  are the two most common 
causes of pediatric HF (Sharma et al 2003, Andrews et al 2008 ).HF can develop or exacerbate 
in childhood, during adolescence and later in adulthood as made evident by the growing number 
of adults with congenital heart disease.
The clinical course and outcome for pediatric HF depends on the etiology. For congenital he art 
disease, corrective surgery  will have a major impact on the clinical course. Following congenital 
heart surgery , HF can still develop for a number of reasons including myocardial systolic 
dysfunction.
Many  pediatric patients with severe HF are usually  listed for heart transplant if available; 
however, cardiac transplantation is usually  a
 last resort given the limited availability  of donor 
organs, complicated clinical course management and associated morbidity  and mortality . In the 
US, one in four infant s listed for heart transplant dies before a donor heart is available ( Mah et 
al2009).
In contrast to HF in adults, there is very limited research in pediatric HF. Consequently , the 
treatment of HF in children is based on info rmation and results provided by adult studies 
(Kantor and Mertens 2010 ). The Diovan Pediatric Heart Failure Survey  study confirmed that 
two factors; ‘efficacy shown in an adult trial’ and ‘Consensus Statements and Guidelines’ were 
the most important factors considered when making treatment decisions for pediatric patients 
with HF (CVAL489K2304 HF Survey  2011). According to this survey  of pediatric cardiologists, 
current clinical management of pedia tric HF includes angiotensin converting enzy me inhibitors 
(ACEI), angiotensin receptor blockers (ARBs), β-blockers, diuretics, aldosterone -blocking 
agents, digoxin and anticoagulants. At present, no trial has demonstrated an outcome benefit of 
any pharmaco therapy  in children with HF.
Entresto (sacubitril/valsartan ), also known as LCZ696 ,is a first-in-class, angiotensin receptor 
neprily sin inhibitor treatment for chronic HF (CHF) and reduced ejection fraction. Nepril ysin 
(NEP) inhibition with chronic 
oral administration of sacubitril/valsartan can promote the 
endogenous capacit y of the body  to compensate for HF exacerbations by potentiating the 
activity  of natriuretic peptides secreted by the heart in response to cardiac stress and increased 
intravascular volume. Sacubitril/valsartan , unlike any other therapy for HF, provides 
concomitant inhibition of NEP and the angiotensin type 1 (AT 1) receptor. The resulting increase 
in natriuretic peptide activity  due to NEP inhibition and AT 1receptor blockade through renin -
angiotensin-aldosterone system (RAAS) inhibition have complementary  effects on the 
cardiovascular (CV) s ystem that benefit HF patients.
In PARADIGM -HF (CLCZ696B2314; N = 8442), the pivotal Phase 3 study  in adult patients 
with HF with reduced ejection fraction (HFrEF), sacubitril/valsartan was superior to enalapril 
(the standard of care) in delay ing time to first occurrence of composite endpoint of CV death or 
HF hospitalization, with a 20% relative risk reduction (RRR) (p = 0.0000002). In addition, 

Novartis Confidential Page 18
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
sacubitril/valsartan was superior to enalapril in delay ing time to CV death with a 20% RRR 
(p=0.00004) and in delay ing time to first HF hospitalization with a 21% RRR (p=0.00004). 
PARADIGM -HF also showed that sacubitril/valsartan is generall y safe and well tolerated in 
adult patients with HF ( McMurray et al 2014).
Study  CLCZ696B2319 (PANORAMA -HF)is alarge, multicenter, double -blind, active 
controlled pediatric HF trial and includes patients with systemic left ventricular systolic 
dysfunction <18 yearsof age. PANORAMA -HF is designed to demonstrate whether 
sacubitril/valsartan provides greater clinical treatment benefit than enalapril as well as to assess 
its safety  profile compared to enalapril over a 52-week treatment duration.
The collection of long-term safety  and tolerability  data in a pediatric population is equally 
important, as patients may be dependent 
on HF medication for a long period of time. For this 
purpose, upon successful completion of the 52-week double -blind treatment period in 
PANORAMA -HF, patients will be offered the opportunity  to enroll in thisopen -label ,long-
term extension study  and receive open -label sacubitril/valsartan treatment. For subjects who 
may have successfull y completed the double -blind study  before the PANORAMA -HF Open 
Label Extension (OLE)CLCZ 696B2319E1 study  starts at their study  center, participation in 
the OLE will be offered to them once the stud y is avai lable.
1.2 Purpose
The purpose of this study  is to evaluate long-term safety  and tolerability  and to provide post-
trial access to sacubitril/valsartan to eligible CL CZ696B2319 (PANORAMA- HF) patients. 
2 Objectives and endpoints
The primary  objective is to furthe r evaluate long-term safet y and tolerability  of
sacubitril/valsartan in eligible PANORAMA -HF subjects receiving open -label 
sacubitril/valsartan . 
There are no secondary  or exploratory  objectives for this study .
Table 2
-1 Objectives and related endpoints 
Objective(s) Endpoint(s)
Primary  Objective(s) Endpoint(s) for primary objective(s) 
To further evaluate long -term safety and 
tolerability ofsacubitril/valsartan in eligible 
PANORAMA -HF subjects receiving open -
label sacubitril/valsartanAEs, SAEs, laboratory values ,vital sign s, and duration 
of drug exposure
Secondary  Objective(s) Endpoint(s) for secondary  objective(s)
Not applicable Not applicable
Exploratory  Objective(s) Endpoint(s) for exploratory  objective(s)
Not applicable Not applicable

Novartis Confidential Page 19
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
3 Study  design
This trial is a multicenter, open -label long-term extension study  for subjects who have 
successfull y completed Part 2 of the PANORAMA -HF trial. PANORAMA -HF is a Phase 3b
study  in pediatric subjects with sy stemic left ventricular s ystolic dy sfunction. 
Only  subjects who successfully  completed the 52-week randomized double -blind treatment 
period of PANORAMA -HF (Part 2, efficacy , safety ) on study  medication (i.e. on dose level 1 
or higher at the PANORAMA -HF End of Study  visit)or who discontinued study  drug treatment 
early in Part 2 due to the implementation of USM of PANORAMA -HFand fulfill protocol 
requirements (see Section 5) are eligible to participate in the OLE,and will be offered the option 
to initiate treatment with sacubitril/valsartan by enrolling into this study  (CL CZ696B2319E1) 
at the discretion of the investigator. Subjects who only  participated in Part 1 of PANORAMA -
HF, who were screen failures in PANORAMA -HFor who permanently  discontinued study  drug 
treatment during Part 2 of PANORAMA -HF for reasons other than the implementation of the 
USM are not eligible for this study  (see Section 5 for details).
For all consenting subjects eligibility  for the OLE will be assessed at the screening visit (Visit 
500) and the study  medication will be initiated no later than 30 day
s after completion of Part 2 
of PANORAMA -HF Visit 416 (see Section 8.1 for details) . 
Required 36 -hour washout:
A 36 -hour washout after the last dose of study  medication taken in the PANORAMA -HF 
study  (Visit 416) is required for all subjects before starting OLE study  medication.  
A 36 -hour washout before starting OLE study  medication is also required for all subjects 
that have transitioned to an ACEI after comple tion of PANORAMA -HF.
An ARB or a renin inhibitor must be discontinued the morning of Visit 501   for subjects taking 
either of these drugs.
Subjects will be enrolled into two different age groups (Age Group 1: 6 years and older; Age 
Group 2: 1 to <6years)in the OLE study . Subjects who turned 18 years old during the 
PANORAMA -HF double -blind study , and who qualify ,are eligible to participate in the OLE 
study .
Age Group s 1 and 2 in the OLE ha vea target dose (dose level 4) of 3.1 mg/kg bid.
Subjects will be up titrated to the target dose of sacubitril/valsartan, dose level 4 (see Table 3 -
2) according to their tolerability . Subjects have to meet all criteria in Table 3-1during the up-
titration phase for safet y monitoring before administering the next higher dose level.  
Visits 502, 503, 504 and 505 , as applicable, are intended to be used for study  drug up -titration 
and abbreviated safet y follow -
up at an interval of appro ximately  2 weeks between the visits. 
During that time, subjects should be up titrated to the maximum tolerated oral dose of 
sacubitril/valsartan with a goal of reaching the target dose of 3.1 mg/kg.(Refer to Table 3-2for 
study -drug dose levels 1 to 4.)

Novartis Confidential Page 20
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Table 3-1 Safety  monitoring criteria for initiation/up -titration of study  drug
Parameter Description
Potassium level Serum K ≤ 5.4 mmol/L (mEq/L) or plasma K ≤ 5.0 mmol/L (mEq/L)
Kidney function eGFR (calculated using the modified Schwartz formula) ≥ 30% mean GFR for 
age ( Appendix 3 , Table 16-6) 
Kidney function eGFR reduction < 35% compared to screening Visit 500. 
Blood pressure SBP > than the calculated 5th percenti le SBP for age as described in 
Appendix 6
AEs or conditions No conditions that preclude continuation according to investigator’s judgment, 
including hypotension.
Table 3-2 Study  drug dose levels for sacubitril/valsartan
age groups 1 and 2 *
Dose levels for pediatric formulation
Dose level 1 0.8 mg/kg bid.
Dose level 2 1.6 mg/kg bid.
Dose level 3 2.3 mg/kg bid.
Dose level 4 3.1 mg/kg bid.
Dose levels for adult formulation
Dose level 1 50 mg bid.
Dose level 2 100 mg bid.
Dose level 3 150 mg bid.
Dose level 4 200 mg bid.
*Note: sacubitril/valsartan target dose (dose level 4) for age group s1 and  2 is 3.1 mg/kg bid. (see 
Section 4.2 for additional details).
If a subject is unable to tolerate up -titration to a higher sacubitril/valsartan dose level or at the 
discretion of the investigator, subjects may be maintained on lower dose levels of 
sacubitril/valsartan (dose level 1-3, see Table 3-2). In case of a consecutive 3-month 
interruption of study  treatment, subject should be discontinued from the study  and should 
complete Visit 599.
An outline of the study  design is presented in Figure 3-1. Depen ding on when and where the 
patient is enrolled, the duration of the study  varies from 1 to approximately  4.5 y ears.
The OLE study  drug starting dose will depend either upon the dose of ACEI /ARB that the 
subject was transitioned to after completion of the PANORAMA -HF or the dose the subject 
was on at the End of Study  visit for the core study  PANORAMA -HF prior to screening (Visit 
500; refer to 
Table 3 -2).
At Visit 501, subjects who meet eligibility  criteria will start the study  drug at dose level 1 or 2 
(Table 3-2). Subjects who were on dose level 1 at the PANORAMA -HF End of Study  
(PANORAMA -HF visit 416) or who are on a low dose of ACEI/ARB (dose levels 1; Table 3 -
3) or not on an ACEI/ARB prior to screening (Visit 500) should start at dose level 1 at Visit 
501.

Novartis Confidential Page 21
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Subjects who were on dose level 2, 3 or 4 at PANORAMA -HF visit 416 or who are on a higher 
dose of ACEI/ARB (dose levels 2, 3 or 4; Table 3 -
3) prior to screening (Visit 500) should start 
at dose level 2 at Visit 501 ( Table 3
-2) or at dose level 1 at investigator’s discretion.
During the study , visits to assess safet y will be conducted at Visit 501 and at 3-months intervals 
until the conclusion of the study  (except for titration visits, which are at 2-week intervals). 
Unscheduled visits are allowed for subject
’s safety  and for dose adjustment purposes
Table 3-3 Total daily  dose levels of commonly  prescribed A CEI/A RBs for the 
purpose of comparing to dose levels of study  drug
Dose levels for 
pediatric formulationEnalapril/Lisinopril 
total daily doseCaptopril total daily 
dose
Dose level 1 0.1 mg/kg 0.3 mg/kg
Dose level 2 0.2 mg/kg 0.6 mg/kg
Dose level 3 0.3 mg/kg 1.2 mg/kg
Dose level 4 0.4 mg/kg 1.5 mg/kg
Dose levels for adult 
formulationEnalapril/Lisinopril 
total daily doseCaptopril total daily 
doseCilazapril total daily 
dose
Dose level 1 5 mg 18.75 mg 0.5 mg
Dose level 2 10 mg 37.5 mg 1.0 mg
Dose level 3 15 mg 75 mg 2.5 mg
Dose level 4 20 mg 150 mg 5.0 mg
Dose levels for 
pediatric formulationValsartan total daily 
doseLosartan total daily 
doseCandesartan total 
daily dose
Dose level 1 0.7 mg/kg 0.4 mg/kg 0.2 mg/kg
Dose level 2 1.4 mg/kg 0.7 mg/kg 0.25 mg/kg
Dose level 3 2.0 mg/kg 1.0 mg/kg 0.32 mg/kg
Dose level 4 2.7 mg/kg 1.4 mg/kg 0.64 mg/kg
Dose levels for adult 
formulationValsartan total daily 
doseLosartan total daily 
doseCandesartan total 
daily dose
Dose level 1 40 mg 25 mg 4 mg
Dose level 2 80 mg 50 mg 8 mg
Dose level 3 160 mg 75 mg 16 mg
Dose level 4 320 mg 100 mg 32 mg

Novartis Confidential Page 22
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Figure 3-1 Study  Design
4 Rationale
4.1 Rationale for study  design
The purpose of this open - label extension study  of PANORAMA -HF is to further evaluate the 
long-term safet y and tolerability  and to provide post-trial access ofsacubitril/valsartan to 
eligible patients that successfully completed the PANORAMA -HF study  (see 
Inclusion /Exclusion criteria Section 5.1).
4.2 Rationale for dose/regimen and duration of treatment
The starting dose will be dose level 1 or 2, based on the dose level the subject was on at the 
final visit of PANORAMA -HF or the dose levels of ACEI/ARBs to which the subject was 
transitioned after completion of the double -blind core study , PANORAMA -HF. The respective 
starting dose levels were chosen to ensure a smooth transition to the open -label study 
medication taking safet y and tolerability  aspects 
into account. Subject swill be up-titrated to 
next dose level at approximately  2-week intervals , per inves tigator judgement, until the target 
dose of 3.1 mg/kg or the maximum tolerated dose is reached.
The duration of the study  will continue up to 2 years from LPLV of part 2 of the core study  (i.e., 
until approximately  Dec-2023), receipt of local marketing authorization and commercial 
availability , or reaching maximum limit allowed by  local regulations, whichever occurs first.  
In countries where the sacubitril/valsartan is already  authorized for pediatric use during the core 
study , patients may participate inthe study  for up to 1 year before being transitioned to 
commerciall y available product. If the formulation the patient is taking is not yet commerciall y 
available at the end of 1 year, the patient may continue in the study  until the formulation 
becomes commerciall y available or any of the above conditions are met (also see details in 
Section 6.1.4).
This timeframe will allow for meaningful capture of long-term safet y data and will ensure 
sufficient access to study  drug, which patients have relied on for their treatment, for an extended 
period until they can obtain it using normal local commercial process . In addition the results of 
w=weeks; m=months; DL=LCZ696 dose level
* ≥36 hour of ACEI or double -blind study medication -free washout before starting OLE study medication at Visit 501
** The starting dose at V501 can vary according to prior dose of AECI/ARBs or PANORAMA -HF study drug

Novartis Confidential Page 23
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
the PANORAMA -HF core study  results will be available during this time frame and will 
determine whether patients in PANORAMA- HF derived benefit from treatment with L CZ696. 
[* The following text applies to subjects enrolled in the OLE in German y: Each eligible subject 
enrolled in German y has a max imum study  duration of 4 years. The treatment duration may be 
re-evaluated at a later time point as needed .]
4.3 Rationale for choice of control drugs 
Not applicable.
4.4 Purpose and timing of interim analy ses/design adaptations
Not applicable.
4.5 Risks and benefits
This is an extension study  for subjects who have successfully  completed the double -blind 
PANORAMA -HF trial, with a goal to further evaluate long-term safet y and tolerability  of
sacubitril/valsartan in pediatric heart failure subjects. 
Details regarding preclinical data from sacubitril/valsartan juvenile animal studies are described 
in the Sacubitril/Valsartan Investigator’s Brochure (IB), which is provided to every 
participating stud y site.
Sacubitril/valsartan has proven to have a significant mortality  and morbidity  benefit compared 
to the standard of care enalapril for the treatment of adult HF with reduced systolic function 
(HFrEF) in the PARADIGM -HF study  (CLCZ696B2314). Continuous treatment with 
sacubitril/valsartan over a median follow -
up time of 27 months led to a 20% RRR in the primary  
endpoint of CV death or first HF hospitalization over optimized enalapril treatment. Clinical 
trial data in adults demonstrate that sacubitril/valsartan has an overall safety  profile generall y 
comparable to other RAS inhibiting agents. Hypotension, hyperkalemia, renal impairment, and 
angioedema have been identified as possible safety  risks in sacubitril/valsartan studies. While 
the incidence rate of hy potension in Study  CLCZ696B2314 was higher for sacubitril /valsartan
compared with enalapril, hypotension assessed as severe or serious was not higher in the 
sacubitril/valsartan group compared to the enalapril group. In addition, no major difference was 
observed for hypotension leading to study  drug discontinuat ion. In contrast, the incidence of 
hyperkalemia, renal impairment and cough was numericall y lower in the sacubitril/valsartan
group compared to the enalapril group.
Data are not yet available from the double -blind study  PANORAMA -HF. An external 
independent Data Monitoring Committee ( DMC )monitors the safety  of the PANORAMA -HF 
study  participants in an unblinded manner. DMC findings (safet y and/or efficacy ) and 
recommendations may impact the conduct of PANORAMA -HF as well as this open -label -
extension study .
Although the DMC regularly  monitors ongoing data in the core study  PANORAMA -HF, one 
risk for patients enrolling in the open -label study  is that, they  are doing so without knowing the 
results of the double -blind core study  PANORAMA -HF. It should also be note d that the long -
term exposure to sacub itril/valsartan on cognitive function is not known.

Novartis Confidential Page 24
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Risksto subjects in this trial (e.g. renal dy sfunction, blood pressure, and hyperkalemia) can be 
minimized by rigorous compliance with the inclusion and exclusion criteria and study  
procedures, as well as clinical safet y monitoring (vital signs, physical exam, hematology , blood 
chemistry and urinal ysis tests) . Recommended guidelines for prophy lactic or supportive 
management of study  drug-induced adverse events are provided in Appendix 4, Appendix 6, 
and Appendix 7(guidelines for the management of renal dysfunction, blood pressure, and 
hyperkalemia , respectively ).
Women of childbearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study , and agree that in order 
to participate in the study they must adhere to the contraception requirements outlined in the 
exclusion criteria. If there is any  concern that the subject will not reliably  comply , they  should 
not be entered or continue in the study .
4.6 Rationale for Public Health Emergency  mitigation procedures
In the event of a Public Health emergency  as declared by Local or Regional authorities i.e. 
pandemic, epidemic or natural disaster, mitigation procedures may be required to ensure 
patients safet y and trial integrit y are listed in relevant sections of the study protocol. Notification 
of the Public health emergency  should be discussed with Novartis prior to implementation of 
mitigation procedures, and permitted/approved by Local or Regional Health Authorities and 
Ethics Committees as appropriate. 
5 Population
The study population consists of pediatric HF patients ≥ 13 months, in -
patients or outpatients. 
Subjects will be divided into two age groups , Age Group 1, ≥ 6 years old and Age Group 2, 13 
months to <6 years old). All patients who safely  tolerated study  drug in PANORAMA -HF, who 
were receiving study  drug at Visit 416 of the double -blind study  or discontinued from study 
drug treatment early due to implementation of the USM and who successfully  completed the 
double -blind study , and fulfilled the Inclusion/Exclusion criteria for the OLE (Section 5.1 and 
Section 5.2) , can be considered for this open -label study . Patients in the double -blind study  for 
whom study  medication h adbeen te mporarily  interrupted during the study, may  be considered 
for the OLE if they were receiving study  medication at Visit 416 and they meet all entry  criteria. 
5.1 Inclusion criteria
Subjects eligible for inclusion in this study  must meet allof the following c riteria:
1.
Signed informed consent as well as assent at an appropriate age based on country  
regulations must be obtained prior to participation in the study .
2.Patient was on study  medication at the PANORAMA -HF Part 2 End of Study  visit (Visit 
416) or disconti nued from the study  drug treatment earl y due to the implementation of the 
USM and does not have any  significant safety  issue as determined by  theinvestigator.  
Based on the investigator judgement, the patient is able to safel y enroll in the OLE stud y.

Novartis Confidential Page 25
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
5.2 Exclusion criteria
Subjects meeting an y of the following criteria are not eligible for inclusion in this study .
1.Patient who only  participated in Part 1 of the PANORAMA- HF stud y or was a screen 
failure in PANORAMA -HF or permanentl y discontinued study  drug in Part 2 of the 
PANOR AMA-HF study for reasons other than the implementation of the USM.
2.Use of investigational drugs within 5 half -lives of enrollment or within 30 day s whichever 
is longer; or longer if required by  local regulations –with the exception of PA NORAMA -
HFstudy  drug. For PANORAMA- HF stud y drug ( sacubitril/valsartan /placebo; 
enalapril/placebo), a minimum of 36-hour washout period is required before the initiation 
of study  treatment (Visit 501).
3.History  of hypersensitivity  or allergy  to an y of the study  treatments or its excipients or to 
drugs of similar chemical classes, ACEIs, ARBs, or NEP inhibitors as well as known or 
suspected contraindications to sacubitril/valsartan .
4.Renal vascular h yperten sion (including renal artery  stenosis).
5.
Patients with significant renal (eGFR calculated using the modified Schwartz formula < 
30% mean GFR for age, Appendix 3 , Table 16-6); hepati c (serum aspartate 
aminotransferase or alanine aminotransferase > 3 times upper li
mit of normal); 
gastrointestinal or biliary disorders (that could impair absorption, metabolism, or excretion 
of orall y administered medications).
6.Patients with a history  of angioedema.
7.Patients who have parents or legal guardians who do not give consent or allow the child to 
give assent, or inability  of the patient or the parents/legal guardians to follow instructions 
or comply  with follow -up procedures.
8.Pregnant or nursing ( lactating) women.
9.Any medical condition(s) that may  put the patient at risk in the investigator’s opinion, or 
that the investigator deems unsuitable for the study .
10.Patient breastfed b y a mother taking ACEI.
11.Women of child-bearing potential, defined as all women phy siologicall y capable of 
becoming pregnant, unless they are using highly  effective methods of contraception while 
taking stud y treatment and for 5 day sof sacubitril/valsartan after stopping medication. 
Highl y effective contraception methods includ e:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject. Periodic abstinence (e.g. calendar, ovulation, sy mptothermal, post
-ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total h ysterectom y, or tubal ligation at least six weeks before taking 
study  treatment. In case of oophorectom y alone, only  when the reproductive status of 
the woman has been confirmed by  follow -up hormone level assessment
Male sterilization (at least 6 months prior to screening). For female subjects on the 
study , the vasectomized male partner should be the sole partner for that subject
Use of oral (estrogen and progesterone), injected ,or implanted hormonal methods of 
contraception or placement of an intrauterine device (IUD) or intrauterine sy stem 
(IUS), or other forms of hormonal contraception that have comparable efficacy  

Novartis Confidential Page 26
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
(failure rate <1%), for example, hormone vaginal ring or transdermal hormone 
contraception.
In case of use of oral contraception ,women should have been stable on the same pill for a 
minimum of 3 months before taking stud y treatment.
Women are considered post- menopausal and not of child -bearing potential if they  have had 12 
months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age 
appropriate history of vasomotor symptoms) or have had surgical bilateral oophorectom y (with 
or without hysterectom y), total hysterectomy ,or tubal ligation at least six weeks ago. In the 
case of oophorectomy  alone, only when the reproductive status of the woman has been 
confirmed by follow -up hormone level assessment is she considered not of child bearing 
potential.
If local regul ations deviate from the contraception methods listed above to prevent pregnancy , 
local regulations appl y and will be described in the informed consent form ( ICF).
6 Treatment
6.1 Stud y treatment
6.1.1 Investigational and control drugs
Table 6-1 Open -label sacubitril/valsartan formulations
Formulation Strength Comments
capsule containing 4 granules
(3.125 mg/granule)12.5 mg capsules in bottle s
capsule containing 10granules
(3.125 mg/granule)31.25 mg capsules in bottle s
tablets 50 mg tablets in bottles
tablets 100 mg tablets in bottles
tablets 200 mg tablets in bottles
liquid suspension please refer to OLE Pharmacy Manual
The sacubitril/valsartan study  medication is available in 3 formulations: tablets, granules (mini -
tablets) or liquid formulation (Table 6-1). For liquid formulation, please refer to the OLE 
Pharmacy  Manual. 
All pediatric formulations of study  medicat ion (
sacubitril/valsartan granules or liquid) will be 
made available to all age groups. The adult tablet formulations of sacubitril/valsartan will be 
available for subjects based on the subject’s dosing and ability to swallow adult tablets (refer to 
OLE Pharmacy  Manual). The dispensing of medication to the subjects will be controlled by an 
Interactive Response Technology  (IRT) sy stem based on the dose level, subject’s body  weight 
and ability  to swallow tablets/granules.
An overview of available sacubitril/valsartan formulations is illustrated in Table 6 - 1. Capsules 
of LCZ696containing 4 granules or 10 granules per capsule will be provided for oral use. The 
granules can be swallowed by the subject, after the removal of the outer capsule. Subjects who 

Novartis Confidential Page 27
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
cannot use tablets or granules can use the liquid formulation. Sacubitril/valsartan liquid 
formulation will be com pounded by the site / pharmacy  (please refer to OLE Pharmacy  Manual). 
Sufficient medication will be provided for treatment according to the study  protocol. 
Medication labels will be in the local language and comply  with the legal requirements of the 
country . The labels will include storage conditions for the drug and the medication number, and 
will not include information about the subject.
Subjects taking the liquid formulation of sacubitril/valsartan will need to have a resuppl y every 
4 weeks. Given the burden of traveling to the site for study  visits for subjects and families, the 
parent/caregiver can come to the site without the subject for dispensation of study  drug between 
scheduled study  visits (see Table 8
-1). Delivery  of study  drug to the subject can also be used, 
where possible and where allowed b
y local regulations. 
6.1.2 Additional study treatments
No other study  treatment
sbeyond the investigational treatment (sacubitril/valsartan) are 
planned for this trial.
6.1.3 Treatment arms/group
There is 1 treatment arm in this open -label study . All subjects will receive open -label 
sacubitril/valsa rtan.
6.1.4 Treatment duration
The study  will continue
up to 2 years from LPLV of part 2 of the core study  (i.e., until 
approximately  Dec-2023), receipt of local marketing authorization and commercial availability , 
or reaching maximum limit allowed by  local regulations, whichever occurs first.  
In countries where the sacubitril/valsartan is already  authorized for pediatric use during the core 
study , patients may participate in the study  for up to 1 year before being transitioned to 
commerciall y available product. If the formulation the patient is taking is no t yet commerciall y 
available at the end of 1 year, the patient may continue in the study  until the formulation 
becomes commercially  available or until the maximum limit allowed by local regulations or 
until Dec- 2023, whichever occurs first.
6.2 Other treatment(s)
Subjects may be on a HF regimen throughout the study  duration on the investigator’s discretion ,
except for the use of ACEI , ARBs and renin inhibitors, which are strictl y prohibited. Prohibited 
and important concomitant medication sduring the conduct of the clinical trial are listed below.
6.2.1 Concomitant therapy
The investigator must instruct the subject to notify  the study  site about any new medications 
he/she takes after the subject was enrolled into the study .
All medications, procedures and sig nificant non-drug therapies (including physical therap y and  
blood transfusions) administered after the subject was enrolled into the study must be recorded 
on the appropriate Case Report Forms.

Novartis Confidential Page 28
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt the investigator should contact the Novartis medical monitor before 
enrolling a subject or allowing a new medication to be started. If the subject is alread y enrolled, 
the investigator should contact Novartis to determine if the subject should continue participation 
in the study .
6.2.1.1 Permitted concomitant therapy  requiring caution and/or action
The active metabolites of sacubitril (sacubitrilat) and valsartan are OATP1B1, OATP1B3 and 
OAT3 substrates; valsa rtan is also a Multidrug resistance protein 2 (MRP2 )substrate. Therefore, 
co-administration of sacubitril/valsartan with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. 
rifampin, cyclosporine) or MPR2 (e.g. ritonavir) may increase the systemic exposure to 
sacubitrilat or valsartan, respectivel y. The investigator should exercise appropriate care when 
initiating or ending concomitant treatment with such drugs.
The co-administration of sacubitril/valsartan has increased maximum plasma concentration of 
atorvastatin . These effects may potentiall y be due to the OATP1B1 and OATP1B3 inhibitory 
effects of sacubitril. Therefore, caution is recommended when co-administering 
sacubitril/valsartan with atorvastatin and other statins that are substrates of OATP1B1 and 
OATP1B3.
Antihy pertensive medication should be co-administered with caution due to blood pressure 
lowering characteristics of the study  medication sacubitril/valsartan . 
Medications known to raise potassium levels (e.g. potassium- sparing diuretics, potassium 
suppl ements) should be used with caution. In case of hyperkalemia adequate measures should 
be considered, e.g. reduce dietary  potassium and/or adjust the dose of concomitant 
medication(s). Monitoring of serum potassium is recommended especiall y in subjects with risk 
factors.
In subjects with compromised renal function, concomitant use of sacubitril/valsartan and Non-
steroidal anti-inflammatory  drugs (NSAIDs )may lead to an increased risk of worsening of renal 
function. Therefore, monitoring of renal function is recommended when initiating or modify ing 
treatment in subjects on sacubitril/valsartan who are taking NSAIDs concomitantly .
Guidelines for the managem ent of hyperkalemia, hypotension and renal dysfunction are 
provided in Appendix 7 , Appendix 6 ,and Appendix 4, respectively.

Novartis Confidential Page 29
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
6.2.2 Prohibited medication
Use of the treatments included in the below table are not allowed while taking study  drug due 
to safet y reasons. If the medication included in Table 6-2must be administered, study  drug must 
be discontinued and the actions specified below must be taken.
Table 6-2 Prohibited medications
Medication Prohibition 
periodAction taken
any ACEI36 hour washout 
periodDiscontinue study drug. ACEI must be stopped
for 36 hours prior to re -initiation of study drug. 
any ARBDiscontinue study drug. ARB must be stopped for prior to 
re-initiation of study drug.
renin inhibitor 
(aliskiren)Discontinue study drug. Renin inhibitor must be stopped 
prior to re -initiation of study drug. 
ACEIs, A RBs, and renin inhibitors
The concomitant use of open -label ACEI, ARB, or renin inhibitor is strictly  prohibited while 
the subject is receiving study  drug. If the investigator believes the addition of an ACEI, ARB 
or renin inhibitor is required, the study  drug must be temporarily  discontinued. Study  drug must 
be stopped 36 hours prior to starting open -label ACEI . Study  drug must be stopped prior to 
starti ng open- label ARB or renin inhibitor. Similarly , if study  drug is to be restarted, the open -
label ACEI must be stopped ≥ 36 hours prior to resuming study drug. Open -label ARB or renin 
inhibitor must be stopped prior to resuming stud y drug.
6.2.3 Rescue medication
If in the opinion of the investigator, the subject does not tolerate the assigned study  medication, 
the investigator should consider whether non-disease -modify ing medication [e.g. calcium 
channel blockers ( CCBs ), diuretics, α -blockers ]could be adjusted to rectify  the situation. 
Guidance on handling renal dysfunction, hypotension, and hyperkalemia are provided to 
investigators in Appendix 4 , Appendix 6, and Appendix 7, respectively. 
The investigator may prescribe any  medications and/or supportive care during the study  based 
on clinical needs (excluding use of the prohibited medications described above). Use o f rescue 
medication and/or supportive care must be recorded on the Concomitant medications eCRF.
6.3 Subject numbering andtreatment assignment
6.3.1 Subject numbering
Each subject is identified in the study  by a Subject Number (Subject No.), that is assigned when 
the subject is first enrolled for screening and is retained as the primary identifier for the subject 
throughout his/her entire participation in the trial. The Subject No. consists of the Center 
Number (Center No.) (as assigned by  Novartis to the investigat ive site) with a subject number 
suffixed to it, so that each subject is 
numbered uniquely  across the entire database. Upon signin g 

Novartis Confidential Page 30
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
the informed consent form, the subject will be assigned the same Subject Number as he/she had 
in the PANORAMA- HF core stud y.
Upon signing the informed consent form, the investigator or his/her staff will contact the IRT 
and provide the requested identify ing information to register the subject into the I RT s ystem.
If the subject fails to be treated for an y reason, the IRT must b e notified as soon as possible that 
the subject was not treated. The reason for not being treated will be entered on the Screening 
Disposition eCRF.
6.3.2 Treatment assignment
This is an open -label study  and subjects will not be randomized to treatment in this trial. All 
eligible subjects previously  treated with sacubitril/valsartan or enalapril in PANORAMA -HF 
will be treated with open -label sacubitril/valsartan at maximally  tolerated doses up to the target 
dose that has been determined for each age group. The target dose of sacubitril/valsartan will 
be 3.1 mg/kg bid for Age Group 1.The target dose for Age Group 2 is 3.1 mg/kg bid(see 
Section 4.2 for additional details).
An Interactive Response Technology (IRT) system will be used to enroll subjects into the study 
and dispense study  drug. The investigator or his/her delegate will contact the IRT after 
confirming that the subject fulfills all of the inclusion/exclusion criteria. The IRT system will 
prompt the investigator to enter the subject’s Subject Number into the system and will then 
assign a uniquel y numbered medication kit for the first investigational treatment to be dispensed 
to the subject (at the time of completin g Visit 501).
The IRT will be used to assign additional uniquely  numbered medication kits at subsequent 
visits throughout the duration of the trial (except End of Study  visit).
6.4 Treatment blinding
Not applicable. Treatment will be open to subjects, investig ator staff, persons performing the 
assessments, and the Clinical Trial Team ( CTT ).
6.5 Dose escalation and dose modification
6.5.1 Dose modifications
The study drug is up titrated every 2 weeks as tolerated to target dose ( dose level 4) as outlined 
in Table 3 -2and based on the safet y monitoring criteria ( Table 3 -1). Following up titration, the 
maximum tolerated or target dose will then be maintained for the duration of the study . Both 
scheduled and unscheduled visits can be utilized for up-titration and/or down -titration 
throughout the stud y based on i
nvestigator judgment.
For subject s who are unable to tolerate the protocol -specified dosing scheme, dose level 
adjustments and tempora ry interruptions of less than 3 months of study  treatment are permitted. 
The following guidelines should be followed:
The investigator should adjust/interrupt/discontinue doses of concomitant medications if it 
is believed that they  are the most likely  caus e of an adverse event .

Novartis Confidential Page 31
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
If adjustment/elimination of concomitant medications is not possible or does not alleviate 
the adverse event of concern, the i nvestigator may  down titrate to the next lower study  
drug dose level ( Table 3
-2) to temporary  or permanent discontinuation of study  drug. 
The subject may  reinitiate the higher dose when the investigator feels it is appropriate to 
do so per the directions provided below in this section.
If the stud y drug is permanently discon tinued, the subject should be discontinued from the 
study  (Visit 599).
Subjects may be seen at any time for unscheduled visits during the study  for re-evaluation of 
safet y criteria parameters. Study  drug dose level adjustments should mainly  be based on 
overall 
safet y and tolerability with focus on a) h yperkalemia, b) symptomatic h ypotension and c) renal 
dysfunction. Laboratory assessments of serum sodium, potassium, creatinine, and eGFR 
(calculated based on the modified Schwartz formula (Schwartz and Work 2009 ) will be utilized. 
Refer to Appendix 4, Appendix 6, and Appendix 7for treatment guidelines for renal dysfunction, 
management of h ypotension and hyperkalemia, respectively.
Adjustment of study -drug dose level
During the study , down titration of the study  drug at any time is allowed based on the safet y 
and tolerability  criteri
a defined in Table 3 -1and per the Investigator’s clinical judgement. 
The investigator may down titrate the study  drug to the next lower dose level or may down 
titrate 2 or 3 dose levels (e.g. from dose level 4 to dose level 1), based on their clinical judgement. 
If the tolerability  issues are not alleviated despite down titration by multiple dose levels, the 
investigator may temporarily discontinue study drug. Once the subject’s condition is stable, the 
subject can be up titrated to the next higher dose level using unscheduled visits in an attempt to 
bring back the subject gradually to the target study drug dose level. The investigator may select 
the next dose level for down- or up -titration according to his or her judg ment ( Table 3-2). 
All changes should be recorded on the Drug Administration Record ( DAR )eCRF. In addition, 
IRT should be contacted to register an y changes in the subject’s study -drug dose level, in cases 
of temporary  and permanent discontinuation of the study  drug, and to obtain the medication 
numbers of the stud y drug supplies required for the new stud y-drug dose level.
Study drug restart after temporary  treatment interruption
Subjects who have temporaril y discontinued study  drug should be restarted as soon as possible 
as deemed appropriate by the investigator. The investigator should restar t the subject on the 
study  drug at the most appropriate dose level (Table 3-2) as per the investigator’s clinical 
judgment. If the subject does not tolerate the newly  restarted study -drug dose level, they may 
be down titrated again (if appropriate) or the study  medication may be temporaril y discontinued 
again. 
Subjects restarted on the study  drug will retain their original stud y identification numbers.
Investigators may discontinue a subject's study  drug due to serious or intolerable AEs suspected 
to be causally  related to study  drug. If study  drug is discontinued for any reason, this must be 
recorded on the DAR eCRFs. In addition, subjects who permanently  discontinued study  drug 
should be scheduled for the discontinuatio n study  Visit 599.

Novartis Confidential Page 32
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
If during study  treatment interruption a subject requires treatment with an ACEI  a ≥36 hours 
washout should be observed before the ACEI is initiated. The ACEI must be discontinued ≥36 
hours prior to restarting study  drug. Subjects who have temporaril y discontinued study  drug and 
are presentl y taking an ARB or a renin inhibitor must discontinue their current ARB or renin 
inhibitor on the day  study  drug is restarted.
Note that after a consecutive 3- month interruption of study  treatment, sub ject should be 
discontinued from the study  and should be seen at the site for Visit 599).
If the subject becomes pregnant during the course of the study , the subject has to discontinue 
study  drug immediatel y and should be seen at the site for Visit 599 andevaluated for transition 
to alternative treatment per the Investigator’s clinical judgement .  
Refer to ( Section 8.4.2 ) for further details on pregnancies and reporting guidelines.
6.6 Additional treatment guidance
6.6.1 Treatment compliance
The investigator must promote compliance by instructing the subject/parent/guardian to 
take/administer the study  treatment exactly  as prescribed and by stating that compliance is 
necessary  for the subject’s safety  and the validity  of the study . The subject/pare nt/guardian must 
also be instructed to contact the investigator if he/she is unable for any reason to take the study 
treatment as prescribed.
6.6.2 Emergency  breaking of assigned treatment code
This is an open -label study  therefore emergency  breaking of treatmen t assignment is not 
applicable.
6.7 Preparation and dispensation
Each study  site will be supplied with study  drug in packaging as described under investigational 
and control drugs section.
Medication will be provided as tablets, granules (mini- tablets) or liqu ids. Tablets and granules 
(mini -tablets) will be provided by Novartis to the study  site. Liquid preparation will be provided 
either by the site or by the pharmacy  according to local regulations. For liquid preparation, 
please refer to OLE Pharmacy  Manual.
A unique medication number is printed on the study medication label. 
Investigator staff will identify  the study  medication kits to dispense to the subject by contacting 
the IRT and obtaining the medication number(s). The study medication has a 2 -part labe l (base 
plus tear-off label). Before dispensing the medication kit to the subject, site personnel will 
detach the outer part of the label from the packaging and affix it to the source document.

Novartis Confidential Page 33
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
6.7.1 Handling of study treatment and additional treatment
6.7.1.1 Handling of study  treatment
Study  drug must be received by a designated person at the study site, handled and stored safel y 
and properly , and kept in a secured location to which only  the investigator and designees have 
access. Upon receipt, all study  drugsmust be stored according to the instructions specified on 
the labels and in the Investigator’s Brochure. Clinical supplies are to be dispensed only in 
accordance with the protocol. Technical complaints are to be reported to the respective Novartis 
CO Quality  Assur ance.
Medication labels will be in the local language and comply with the legal requirements of each 
country . They  will include storage conditions for the study  drug but no information about the 
subject except for the medication number. 
The investigator must maintain an accurate record of the shipment and dispensing of study  drug 
in a drug accountability  log. Monitoring of drug accountability  will be performed by  monitors 
during site visits or remotely  and at the completion of the trial. Subjects will be a sked to return 
all unused study  drug and packaging at the end of the study  or at the time of discontinuation of 
study  drug.
At the conclusion of the study , and as appropriate during the course of the study , the investigator 
will return all unused study  drug, packaging, drug labels, and a copy of the completed drug 
accountability  log to the Novartis monitor or to the Novartis address provided in the investigator 
folder at each site.
Where applicable and as per local regulations, the study  medication can be shipped from the 
study  site or pharmacy  to subject’s home. Pharmacy  to home operating procedures will be 
provided to the site/pharmacy  by the sponsor.
6.7.1.2 Handling of additional treatment
The investigator should instruct the subject/parent/guardian to notify  the study  site about any 
new medications he/she/their child takes after the subject was enrolled into the study . All 
medications, procedures and significant non-drug therapies (including physical therapy  and 
blood transfusions) administered after the subjec t was enrolled into the study must be recorded. 
The subject should be receiving optimal standard of medical care or surgical treatment for their 
HF and comorbidities. 
6.7.2 Instruction for prescribing and taking study treatment
Novartis will supply  the investi gators with all study  medications required for the course of the 
study . Subjects will be provided with bottles containing study  drug corresponding to their 
assigned dose level, sufficient to last until the next scheduled visit (Table 8-1). Study  drug will 
be supplied to subjects as:
sacubitril/valsartan tablets: 50 mg, 100 mg or 200 mg 
sacubitril/valsartan granules: 3.125 mg /granule (packaged in capsule containing either 4 or 
10 granules) supplied in a bottle

Novartis Confidential Page 34
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
sacubitril/valsartan liquid formulation (compounded by  site / pharmacy ) (refer to OLE 
Pharmacy  Manual) 
Details regarding preparation of liquid formulation for sacubitril/valsartan are provided in the 
OLE Pharmacy  Manual.
Subjects will be instructed to tak e their morning study  drug doses between 6:00 and 09:00 (6 -
9 AM) and their evening study drug dose between 18:00 and 21:00 (6 -9 PM). The stud y dru gs 
(tablets) should be taken with a glass of water with or without food. For granules and liquid 
administr ation, see OLE Pharmacy  Manual. 
All dosages prescribed and dispensed to the subject and all dose changes during the stud y must 
be recorded on the Dosage Administration Record (DAR) eCRF. All kits of study  treatment 
assigned b y the IRT will be recorded in the IRT system .
The investigator must promote compliance by instructing the subject /parent/guardian to take 
the study  treatment exactly  as prescribed and by stating that compliance is necessary  for the 
subject’s safet y and the validity  of the study . The subject /parent/guardian must also be 
instructed to contact the investigator if he/she is unable for any reason to take the study 
treatment as prescribed .
7 Informed consent procedures
Eligible patients/subjects may  only be included in the study after providing written (witnessed, 
where required by law or regulation), Institutional Review Board /Independent Ethics 
Committee (IRB/IEC )-approved informed consent, or, if incapable of doing so, after such 
consent has been provided by a legally  acceptable representati ve(s) of the patient. In cases 
where the patient’s representative gives consent, the patient must be informed about the study 
to the extent possible given his/her level of understanding. If the patient is capable of doing so, 
he/she must indicate assent bypersonall y signing and dating the written informed consent 
document or a separate assent form. Informed consent must be obtained before conducting an y 
study -specific procedures (e.g. the procedures described in the protocol). The process of 
obtaining info rmed consent and adolescent/child assent where applicable must be documented 
in the patient source documents. 
Novartis will provide to investigators in a separate document a proposed informed consent form 
and age appropriate assent forms that comply with the International Council forHarmoni zation 
of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Good 
Clinic al Practices (GCP )guideline and regulatory requirements and is considered appropriate 
for this study. An y changes to the proposed consent form suggested b y the investigator must be 
agreed to by Novartis before submission to the IRB/IEC, and a copy of the approved version 
must be provided to the Novartis monitor after IRB/IEC approval.
Women of child bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study they  must adhere to the contraception requirement for the duration of 
the study as outlined in the exclusion criteria . If there is any concern that the patient will not 
reliably  comply , they  must not be entered in the study .

Novartis Confidential Page 35
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
As per Section 4.6 , during a Public Health emergency  as declared by Local or Regional 
authorities i.e. pandemic, epidemic or natural disaster, that may challenge the ability  to obtain 
a standard written informed consent due to limits that prevent an on -site visit, if re -consentin g 
the patient on amended informed consent form, the Investigator may conduct the informed 
consent discussion remotely  (e.g. telephone, videoconference) if allowable by a local Health 
Authority . Guidance issued by local regulatory bodies on this aspect prevail and must be 
implemented and appropriately  documented (e.g. the presence of an impartial witness, 
sign/dating separate ICFs by  trial patients and person obtaining informed cons ent, etc.).
Informed consent at study  entry will need to be conducted face-to-face with patients/ caregivers 
following the standard guidelines.
8 Visit schedule and assessments
After identify ing a potential subject, an informed consent form (I CF) and assent 
(if applicable) 
must be signed by the parent(s)/legal guardian(s) and by the subject (as applicable) before 
performing any study -related procedures that are not considered standard of care for pediatric 
HF subjects at that site. Procedures that are part ofa site‘s standard of care for a pediatric subject 
or that were done as part of core study  PANORAMA -HF End of Study  visit 416 may pre-date 
the signed ICF for the OLE. The AE and SAE reporting period will begin at the time the I CF is 
signed ( e.g. screening visit – Visit 500). 
Following the start of sacubitril/valsartan treatment (at Visit 501), initial visits for up titration 
(i.e. Visits 502, 503, 504 and 505) will be scheduled approximately  2 weeks apart.  The number 
of up-titration visits that a subject requires may vary depending upon the starting dose at visit 
501 and the maximally  tolerated/target dose. After the subject’ s target dose is reached, one more 
visit can be scheduled approximately  2 weeks later for a safet y evaluation.
Three (3) months after Visit 501, a telephone visit will occur (Visit 506). The subsequent site 
visits will occur at intervals of 6 months beginn
ing at Visit 507, which is scheduled 6 months 
after starting study  treatment. There will be telephone visits every  3 months in between the in -
person visits. 
Subjects should take their scheduled dose of sacubitril/valsartan in the morning of their study 
visits. Subjects are not required to fast overnight on the day prior to or the day of the study  visit. 
Subjects, who discontinue sacubitril/valsartan for 3 consecutive months, will be discontinued 
from the study  and are to attend Visit 599. 
The Assessment Schedule table (Table 8-1) lists all of the assessments when they are performed 
(indicated with an “x”). All data obtained from these assessments must be supported in the 
subject’s source documentation.
The table indicates which data remain in the source documents only (S). Assessments that 
generate data for database entry  are recorded on eCRFs.
Subjects should be seen for all visits/assessments as outlined in the assessment schedule or 
as 
close to the designated day/time as possible. If one visit is postponed or brought forward, it 
should not result in the next visit being postponed or brought forward. The next visit, if at all 
possible, should adhere to the original schedule in relation to Visit 501. Missed or resc heduled 

Novartis Confidential Page 36
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
visits should not lead to automatic discontinuation. Specific circumstances surrounding missed 
or rescheduled visits must be discussed with the study  monitor. Subjects who prematurel y 
discontinue the study  for any reason should be scheduled for a final visit as soon as possible, at 
which time all of the assessments listed for the final visit ( Visit 599) will be performed. At this 
final visit, all dispensed investigational product should be reconciled, and the adverse event and 
concomitant medication s recorded on the eCRF.
As per Section 4.6, during a Public Health emergency  as declared by Local or Regional 
authorities i.e. pandemic, epidemic or natural disaster that limits or prevents on-site study  visits, 
alternative methods of providing continuing care may be implemented by the investigator as 
the situation dictates. I n case of missed visits/ assessments due to any such events/ disruptions, 
the site must refer to the “Panorama -HF OLE Patient visit guide during Public Health 
Emergencies” document and discuss with the site monitor for guidance on the steps that need 
to be followed for collection of missed data.  

Novartis Confidential Page 37
Amended Clinical Trial Protocol Version 02 (Clean ) Protocol No. CLCZ696B2319E1
Table 8-1 Assessment Schedule
Visit500 501
**502
*503
*504
*505
*50
6†507 508
†509 510
†511 512
†513 514
†515 516
†517 518
520
522
†519 
521
523U
N
S599
Week/MonthScree
ningWk
0Wk
2Wk
4Wk
6Wk
8Mo 
3Mo 
6Mo 
9Mo
12Mo
15Mo
18Mo
21Mo
24Mo
27Mo
30Mo
33Mo
36Mo 
39 
Mo 
45 
Mo 
51Mo 
42 
Mo 
48 
Mo 
54EO
S6 
Obtain Informed 
Consent (parent 
(s)-legal guardian 
(s)/consent -
assent (patient, as 
applicable)1x S
Demography x
Inclusion/Exclusio
n Criteriaxx4
Medical History x
Pediatric Heart 
Failure HistoryS
Concomitant 
Medications5 x x x x x x x x x x x x x x x x x x x x x x
Vital Signs (BP 
and pulse)xx x x x x x x x x x xxx x
Height x x S x S x S x S x
Weight x x x x x x x x x x x x x x x

Novartis Confidential Page 38
Amended Clinical Trial Protocol Version 02 (Clean ) Protocol No. CLCZ696B2319E1
Visit500 501
**502
*503
*504
*505
*50
6†507 508
†509 510
†511 512
†513 514
†515 516
†517 518
520
522
†519 
521
523U
N
S599
Week/MonthScree
ningWk
0Wk
2Wk
4Wk
6Wk
8Mo 
3Mo 
6Mo 
9Mo
12Mo
15Mo
18Mo
21Mo
24Mo
27Mo
30Mo
33Mo
36Mo 
39 
Mo 
45 
Mo 
51Mo 
42 
Mo 
48 
Mo 
54EO
S6 
Head 
Circumference (≤ 
3 years old)x x x x x x
Physical 
Examination 
(complete)S S S S S S S
Physical Exam 
(abbreviated)S S S S S S S S S
Urinalysis x4x x x x (x) x
Serum/Urine 
Pregnancy Test2x4
x x x x x x x x x x x x x x
Complete 
Laboratoriesx4
x x xx6
(x) x
Abbreviated 
Laboratories3 x4x x x x x x xx6
(x)
AEs/SAEs x x x x x x x x x x x x x x x x x x x x x x
Dosage 
Administration 
Recordx x x x x x x x x x x x x x x x x x x (x) x
Study Medication 
ComplianceS S S S S S S S S S S(S
)S

Novartis Confidential Page 39
Amended Clinical Trial Protocol Version 02 (Clean ) Protocol No. CLCZ696B2319E1
Visit500 501
**502
*503
*504
*505
*50
6†507 508
†509 510
†511 512
†513 514
†515 516
†517 518
520
522
†519 
521
523U
N
S599
Week/MonthScree
ningWk
0Wk
2Wk
4Wk
6Wk
8Mo 
3Mo 
6Mo 
9Mo
12Mo
15Mo
18Mo
21Mo
24Mo
27Mo
30Mo
33Mo
36Mo 
39 
Mo 
45 
Mo 
51Mo 
42 
Mo 
48 
Mo 
54EO
S6 
Contact IRT x x x x x x x x x x x x x x x x x x x x x x
Dispense Study 
Medicationsx x x x x x x x x x x x x x x x x x x (x)
End of Study 
Treatment 
Discontinuation x
UNS = Unscheduled visit
S = assessment to be recorded on source documentation only
X = assessment to be recorded in the clinical database or received electronically from a vendor
PSD = Premature subject discontinuation
(x) / (S) = parentheses  indicate that this is an optional assessment
† Visit numbers 506, 508, 510, 512, 514, 516, 518, 520, 522 are telephone visits. 
1 Patient Assent document is captured as a source document and is not stored in the clinical database.
2 For child bearing potential fema les (CHBP) only. Urine pregnancy test is analyzed locally and done at all in-person scheduled/unscheduled visits on all female subjects 
≥11 years of age and all female subjects who are <11 years of age if they are menstruating. A serum pregnancy test is performed and analyzed at Visit 500 (if >14 days 
after PANORAMA -HF EOS visit) and at Visit 599 respectively.  Additionally, for all CHBP, a urine pregnancy test will be performed at monthly intervals during the study. 
The monthly urine pregnancy test can be performed either via: 1) monthly study site visits for urine pregnancy tests, or 2) providing the subject with urinary pregna ncy tests 
for home monthly tests. See Section 8.4.2 for additional details. 
3 Abbreviated laboratories consist of serum sodium, potassium, creatinine, eGFR (modified Schwartz formula). 

Novartis Confidential Page 40
Amended Clinical Trial Protocol Version 02 (Clean ) Protocol No. CLCZ696B2319E1
Visit500 501
**502
*503
*504
*505
*50
6†507 508
†509 510
†511 512
†513 514
†515 516
†517 518
520
522
†519 
521
523U
N
S599
Week/MonthScree
ningWk
0Wk
2Wk
4Wk
6Wk
8Mo 
3Mo 
6Mo 
9Mo
12Mo
15Mo
18Mo
21Mo
24Mo
27Mo
30Mo
33Mo
36Mo 
39 
Mo 
45 
Mo 
51Mo 
42 
Mo 
48 
Mo 
54EO
S6 
4If Visit 500 is scheduled within 14 days of the PANORAMA -HF End of Study visit (Visit 416) and lab results from Visit 416 are available at Visit 500, the assessment results 
from PANORAMA -HF End of Study visit can be used for Visit 500 instead , except thes e discontinued study drug treatment early due to the implementation of the USM . Visit 
501is the visit forfirst drug administration. The inclusion/exclusion criteria and the abbreviated local lab at Visit 501may be performed per the investigator’s clinical 
judgement (e.g., if it is believed that the patient’s health status may have changed since the screening visit) (See Section 8.1 for details). Note: In addition to the scheduled 
complete and abbreviated laboratories per the Assessment Schedule, laboratory evaluations may also be performed at any scheduled or unscheduled visit based on the 
investigator’s clinical judgement.
5 Includes Prior and Concomitant Heart Failure Medications 
6Complete labs at V521 and abbreviated labs at V519 and V523. If the EOS coincides with a scheduled visit, the assessments of EOS visit will take precedence. 
* Visits 502 (Week 2), 503 (week 4), 504 (week 6) and 505 (week 8) are for up-titration purposes and safety evaluation. Number of visits can vary dependent on starting 
dose (DL1 or DL2) and max imal tolerated/target dose. After subject’s target dose is achieved, one more visit can be scheduled approximately within the next 2 weeks for 
safety evaluation , subsequent visits are optional up to visit 506 (3 months).
** Visit 501 must occur within 30 days following completion of PANORAMA-HF core study Visit 416 (See Section 8.1 for details).

Novartis Confidential Page 41
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
8.1 Screening
Please refer toTable 8-1, Assessment Table, for the information to be collected during the 
Screening visit. All consenting subjects will be assessed for eligibility  at the screening (Visit 
500). 
Complete laboratory  tests at Visit 500 as indicated in Table 8-11 & Table 8-3should be 
conducted to assess eligibility .  
The Investigator can use complete lab results from Visit 416 of PANORAMA -HF,except 
those who discontinued s tudy drug treatment earl y due to the implementation of the USM , 
for Visit 500 to evaluate the OLE screening criteria when: 1) Visit 500 is conducted within 
14 days from Visit 416, and 2) when Visit 416 results are available at the time of Visit 500.
In thecase where a safety  laboratory  value at screening is outside of the range specified in 
the exclusion criteria, the assessment may be repeated once prior to 
Visit 501 ( please see
details for re-screening in Section 8.1.1) . If the repeat value remains outside of the specified 
ranges, the subject must be excluded from the study .
Visit 501 is the 
visit for first drug administration. The inclusion/exclusion criteria and the 
abbreviated local lab at Visit 501 may be performed per the investigator’s clinical judgement 
(e.g., if it is believed that the patient’s health status may have changed since the screening visit 
laboratory  assessment was performed).  
Visits 500 and 501 andall their procedures, including all required screening procedures and 
safet y labs, must be completed such that the study  medication is initiated no later than 30 day s 
after Visit 416 of the core study . 
Before starting OLE study  medication at Visit 501, a 36- hour double -blind study 
medication/ACEI -free washout is required after the last dose of study  medication taken in the 
PANORAMA -HF study (Visit 416) and for those that have transitioned to an ACEI after 
completion of PANORAMA -HF, the core study .
8.1.1 Informa tion to be collected on screening failures
Subjects or parents/guardians who sign an informed consent form for themselves or for their 
child, respectively , and who (i.e. the subject) are subsequentl y found to be ineligible for 
this 
study , will be considere d a screen failure. The reason for screen failure should be entered on 
the applicable Case Report Form. The baseline characteristics, demographic information, 
informed consent, and Inclusion/Exclusion pages must also be completed for screen failure 
subject s. No other data will be entered into the clinical database for subjects who are screen 
failures, unless the subject experienced a serious adverse event during the screening phase (see 
SAE section for reporting details).
Subjects or parents/guardians who sign an informed consent for themselves or for their child, 
respectivel y, and who are considered eligible but fail to be started on treatment for any  reason 
will have to discontinue the study and will be considered an early study termination. The reason 
forearly  study termination should be captured on the appropriate disposition Case Report Form 
at Visit 599. 

Novartis Confidential Page 42
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Re-screening:
The investigator may consider re-screening a screen failure subject if he/she believes that the 
subject’s condition has changed and they may potentially  be eligible. Re-screening should be 
arranged as soon as possible to ensure initiation of study  treatment (Visit 501) within 30 days 
after Visit 416 of the PANORAMA -HF core study . The subject (if applicable) /parent(s)/legal 
guardian(s) fo r the subject must provide new written informed consent before when the subject 
is re-screened. Subjects required to provide assent must also provide new assent before being 
re-screened.
8.2 Subject demographics/other baseline characteristics
Country  specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with eCRF.
Subject demographic and baseline characteristic data will be collected including: year of birth 
(where allowed)  age in y ears (age in mo nths for subjects < 2 years, where allowed), sex, race 
and ethnicity , as well as the Identification Number (ID No.) the subject was formerl y assigned 
in the PANORAMA -HF study  (CLCZ 696B2319). Additionally , vital signs, weight and height 
will be collected. Relevant medical history /current medical condition data includes data until 
the start of study  drug. (Information regarding pediatric heart failure history  will be recorded 
only in source documentation.) HF medications will be recorded on the Concomitant 
Medications eCRF.
8.3 Efficacy
Efficacy  will not be measured in this study .
8.4 Safet y/Tolerability
The Sponsor may request additional information on specific adverse events or laboratory  events 
of interest and may make requests to perform additional diagnostic tests to further assess the 
safet y profile of sacubitril/valsartan . Such information may include diagnostic procedure 
reports, discharge summaries, autops y reports, and other relevant information that may  help in 
assessing the reported adverse event. All addit ional information will be de-identified prior to 
collection by  Novartis or its agents.
In addition to AE/SAEs, the following safety- related evaluations will be done:
Physical examinations (data recorded onl y in source)
Vital signs
Height, weight, and head circumference (head circumference is only  collected in subjects 
who are ≤3 years of age at enrollment)
Laboratory  evaluations
Pregnancy
Angioedema
Safety  assessments are specified below with the assessment schedule detailing when each 
assessment is to be performed.

Novartis Confidential Page 43
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
For details on AE collection and reporting, refer to AE section (Section 10.1 ) .
Table 8-2 Physical A ssessments
Assessment Specification
Physical 
examinationA complete physical examination will include the examination of general 
appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, 
heart, abdomen, back, ly mph nodes, extremities, vascular, and neurologi cal. If 
indicated based on medical histor y and/or s ymptoms, rectal, external genitalia, 
breast, and pelvic exams will be performed.
An abbreviated physical exam will include the examination of general 
appearance and vital signs ( systolic and diastolic blo od pressure [SBP and 
DBP] and pulse) as well as other examinations based on the investigator’s 
discretion. . 
Information for all physical examinations must be included in the source 
documentation at the study site. Clinically relevant findings that are pre sent 
prior to signing informed consent must be recorded as medical histor y on the 
appropriate eCRF. Significant findings made after signing informed consent 
which meet the definition of an Adverse Event must be recorded as an adverse 
event on the correspon ding eCRF.
Vital signVital signs include BP and pulse measurements and are assessed when a 
complete or abbreviated physical examination is performed. After the subject 
has been sitting for approximately 5 minutes, with back supported and both 
feet placed on the floor, s ystolic and diastolic blood pressure will be measured 
using an automated validated device, e.g. OMRON, or a standard 
sphygmomanometer with an appropriately sized cuff on the non -dominant arm.
Supine BP instead of sitting BP will be measured in subjects who are infants or 
who cannot sit comfortably. Clinically notable vital signs are defined in 
Appendix 1 .
Height, weight 
and head 
circumferenceHeight/ length in centimeters (cm) .It is recommended to measure s tanding 
height using a stadiometer without shoes .
Body weight (to the nearest 0.1 kilogram (kg) in indoor clothing, but without 
shoes) will be measured at ever y site visit. Body weight during hospitalization 
is to be recorded only if available as per standard of care.
For subjects ≤ 3 years, head circumference in centimeters (cm) is measured .
8.4.1 Laboratory  evaluations
Complete laboratory  evaluations (hematology, blood chemistry, and urine) as outlined inTable 
8-3are performed at screening (Visit 500), and subsequently  every 12 months from Visit 501
(Week 0) until End of Study ( Visit 599). 
Complete laboratory  evaluations will be performed at 
central labor atory  facilities.
Abbreviated safet y laboratory  evaluation consists of serum sodium, potassium, creatinine, and 
eGFR (Table 8-3). Abbreviated laboratory  evaluations are to be performed every  12 months 
starting from 
month 6 (Visit 507) at the central laboratory when possible , as indicated in Table 
8-1. 
In addition, abbreviated l aboratory  assessments should be performed at up-titration visits (Visits 
502, 503, 504 and 505 , as applicable ), and unscheduled visits with planned dose level changes 
and should be performed locally . Local laboratory  results will allow investigators to proceed 

Novartis Confidential Page 44
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
with study  visit procedures without the need to wait for central laboratory  results. The local
laboratory  results must be recorded in the appropriate eCRF. Given limitations of blood volume, 
the local laboratory  assessments will be a priority  for urgent medical decision-making 
(including for study -drug dose titration).
Details on the collections, shipment of samples and reporting of results by the central laboratory 
will be provided to the investigators in the Laboratory  Manual. If the central laboratory  is 
unavailable and/or when dose level changes are intended (either for abbreviated or complete 
labs), the local laboratory should be used.
Local and central laboratory  results need not agree in reported results and reference ranges. The  
Investigator should use his/her clinical judgement on how to best manage the safet y of the 
patient when making de cisions. 
Clinically  notable laboratory  findings are defined in Appendix 1. These findings must be 
commented on by the investigator in the source documents and additional laboratory 
evaluations may  be required, as judged appropriate by  the investigator.
If the laboratory  abnormality  induces clinical signs or symptoms, or requires therapeutic 
intervention, and satisfies the criteria defined in Section 10 Safety  reporting, then the diagnosis 
or medical condition must be entered on the AEs page of the subject's eCRF and any treatment 
necessary  should be documented. If the laboratory  abnormality  is the primary  reason for an 
unforeseen hospitalization or otherwise fulfills the seriousness category  of an AE, then the 
procedure for rapid notification of SAEs must be followed.
Likewise, if the laboratory  abnormality  leads to discontinuation of the study  drug, the subject 
must be followed until the abnormality  resolves or until it is judged to be permanent. This 
investigation may include continued monitoring by repeat laboratory  testing or by
 performing 
additional laboratory  tests as deemed necessary  by the investigator or the Sponsor’s medical 
monitor.
For child bearing potential females only, serum pregnancy  testing will be performed at 
screening (visit 500), and End of Study  visit (
Visit 599). Please see details in Section 8.4.2. 
A table, which provides the maximum, allowable blo
od-draw volumes b y weight, can be found 
in Appendix 8 .
There are countries where plasma potassium is used instead of serum potassium for routine 
clinical care. Plasma potassium can be used instead of serum potassium in this study .Serum 
potassium thresholds in the study  protocol, including those values cited in Appendix 1and 
Appendix 7can be converted to plasma potassium threshol ds for the study  by subtracting 0.4 
mmol/L  from the serum potassium threshold.

Novartis Confidential Page 45
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Table 8-3 Laboratory  Assessments
Hematology Biochemistry Urine measurements**
Hematocrit Alanine aminotransferase (ALT) Specific gravity
Hemoglobin Albumin (Alb) pH
Platelet count Alkaline phosphatase (ALP) Glucose
Red blood cell count (RBC) Aspartate aminotransferase 
(AST)Protein (Total)
White blood cell count (W BC) Blood urea nitrogen (BUN) Ketones
WBC differential Calcium Bilirubin
Magnesium Urobilinogen
Phosphate Hemoglobin (blood)
Red blood cell distribution width 
(RDW)Chloride Leukocyte esterase
Mean corpuscular volume 
(MCV)Creatinine* Nitrite
Mean corpuscular hemoglobin 
concentration (MCHC)Glucose WBC
Potassium* RBC sediments
Sodium* Hyaline casts
Bicarbonate Granular casts
Total bilirubin (TBL) Waxy casts
Fractionated bilirubin (if total 
bilirubin >2 x ULN)WBC casts
Total protein RBC casts
Uric acid
eGFR*
*Abbreviated laboratory evaluations must include these parameters . eGFR should be calculated based 
on most recently available height.
**Urinalysis with dipstick includes specific gravity, pH, glucose, total protein, bilirubin, ketones, 
urobilinogen, nitrite, leukocytes esterase and hemoglobin (blood). Other urine measurements listed are 
not required. If a urine dipstick is positive, other urine measurements such as a qualitative microscopic 
determination of WBC, RBC sediments (and casts) should also be measured.
8.4.2 Pregnancy  and assessments of fertility
Pregnancy  
All child- bearing potential female subjects who are not surgicall y sterile will have pregnancy 
testing. Additional pregnancy  testing might be performed if requested by  local requirements.
Serum pregnancy  testing will be performed at screening (Visit 500), and End of Study  visit 
(Visit 599). Childbearing potential females (CHBP) are defined as all female subjects ≥ 11 years 
of age and all female subjects who are <11 years of age if they are menstruating. Pre-menarchal 
girls <11 years of age should notify  the study  site ifthey start menstruating after the study  has 
started so pregnancy testing can be initiated. Urine pregnancy test is analy zed locally  and done 
at all in-person scheduled/unscheduled visits on all CHBP female subjects. If screening visit 
(Visit 500) is scheduled within 14 daysafter PANORAMA -HF End of Study  visit for the 

Novartis Confidential Page 46
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
subject, no serum pregnancy test will be performed ,only urine pregnancy  testwill be needed 
(seeTable 8-1for additional details regarding pregnancy  testing) . A positive urine pregnanc y 
test should be confirmed with a serum pregnancy  test. Subjects with a positive serum pregnanc y 
at any time in the study  must be disco
ntinued immediately from the study  and should be seen 
at the site for Visit 599 . 
For child- bearing potential females, a urine pregnancy  test will also be performed at monthly 
intervals between stud y visits, during the stud y. Based on local regulatory  requ irements and/or 
cultural differences across participating countries, the between -study -visit monthly  urine 
pregnancy  test can be performed either via: 1) monthly  study  site visits for urine pregnancy 
tests, or 2) providing the subject with urinary  pregnanc y tests for home monthly tests. 
If monthl y home urine pregnancy tests are utilized, child -bearing potential female subjects will 
be given a urine pregnancy  test kit for each month between study  visits and will be instructed 
to perform a urine pregnancy  test at home, once per month (approximately  every 30 days). 
Subjects will be given a Pregnancy  Test Diary  in which they are to record the date and the 
results of their pregnancy  tests that are done at home, each time they run the test. Where possible, 
Study  Site personnel will contact the subject on a monthly  basis to check that the subject has 
completed the urine pregnancy  test and has recorded the result in the Pregnancy  Test Diary . 
The Study  Site personnel may also ask for the result of the pregnancy  test.The contact by the 
Study  Site personnel and the result of the pregnancy  test will be documented in the source 
documentation for the subject. The Pregnancy Test Diary  will be part of the source 
documentation for the subject. If the pregnancy  test is positi ve, the subject/parents/guardian 
must contact the investigator immediately . The aforementioned pregnancy  testing (i.e. done at 
home or at the study  site) will be maintained during treatment and until the end of relevant 
systemic exposure.
All menarchal gir ls and their parents/caregivers should be informed about the potential risks of 
pregnancy  and the need to prevent pregnancy  during the study. It is important to be sensitive in 
introducing this issue, as understanding and comprehension of puberty , sexual activity, 
pregnancy  and contraception is influenced by  age; as well as, factors such as precocit y, socio-
educational economic and familial background. These discussions are therefore best performed 
by investigators familiar with the pediatric subject and her family  and should be guided by 
requirements of the local regulatory authorities. These discussions should take into account the 
socio- economic, cultural factors and religious beliefs of the adolescent participant and her 
family . The i nvestigator should a lso discuss the management of the pregnancy test results with 
the subject and her parents/caregivers. The privacy  of the subject should be considered in 
accordance with the local law and ethics.
Any subject with a positive pregnancy test must discontinue s tudy drug immediately, should be 
discontinued from the study , and should be seen at the site for Visit 599 .
Medical documentation of oophorectom y, hysterectomy , or tubal ligation must be retained as 
source documents. Subsequent hormone level assessment toconfirm the woman is not of child-
bearing potential must also be available as source documentation in the following cases:
1.Surgical bilateral oophorectomy  without a hy sterectomy
2.Reported 12 months of natural (spontaneous) amenorrhea with an appropriate cl inical 
profile.

Novartis Confidential Page 47
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
In the absence of the above medical documentation, Follicle Stimulating Hormone (FSH)
testing is required of an y female subject regardless of reported reproductive/menopausal status 
at screening/baseline.
8.4.3 Other safety  evaluations
Angioedema is a ty pe of abrupt swelling that occurs under the skin and/or mucous membranes 
and is often localized to the head, neck, throat, and/or tongue, but may occur elsewhere, 
including the genitalia and intestines. Severe cases may be associated with airway  compromise.
It is important that the investigator pays special attention to any swelling or edema that may 
resemble angioedema or angioedema -like events that may be reported by subjects. If such an 
event occurs, the investigator will complete angioedema case report forms to summarize the 
event, its treatment, and its ultimate outcome. This report along with the requisite medical 
documentation must be submitted to Novartis as soon as possible. Follow -
up reports must be 
communicated to Novartis as soon as new information regarding the event becomes available. 
All hospital records related to the event must be communicated to Novartis.
The investigator may also be contacted by Novartis and be instructed to complete specific forms 
regarding AEs that may resemble anangioedema -like event. The investigator or his/her 
delegated staff must complete the required forms and provide the required medical records for 
all such events, regardless of whether the investigator views the event in question as 
angioedema or not.
All angioedema reports will be forwarded b y Novartis to an external independent Angioedema 
Adjudication Committee for assessment. Information regarding this committee is outlined in 
Section 
10.2.3. Details on the procedures fo r reporting angioedema events will be provided to 
investigators in a manual.
The study  duration will provide at least 1 year of growth and safet y data in growing children, 
and this will be additional to the 1 y ear of data provided by  the PANORAMA -HF stud y.
8.4.4 Appropriateness of safety  measurements
The safet y and clinical laboratory  assessments performed in this study  are similar to those used 
in the core study  PANORAMA -HF (CLCZ696B2319). These assessments are appropriate for 
an investigational drug with the mechanism(s) of action of sacubitril/valsartan (angiotensin 
receptor neprily sin inhibitor), the safety  profile described in the sacubitril/valsartan Investigator 
Brochure, and the indication/subject population under study .
8.5 Additional assessments
No additiona l tests will be performed on subjects entered into this study .

Novartis Confidential Page 48
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
9 Study  discontinuation and completion
9.1 Discontinuation
9.1.1 Discontinuation of study treatment
Discontinuation of study  treatment for a subject occurs when study treatment is stopped earlier 
than the protocol planned duration, and can be initiated by either the subject or the investigator.
In this study , if the study  treatment is permanently  discontinued, the subject should be 
discontinued from the study  and EOS visit (Visit 599) should be conducted ( Section 6.5.1).
The investigator must discontinue study  treatment for a given 
subject if, he/she believes that 
continuation would negatively  impact the subject's well -being.
Study  treatment must be discontinued under the following circumstances:
Subject/guardian decision
Pregnancy
Use of prohibited treatment as per recommendations in the prohibited treatment section
Any situation in which study  participation might result in a safet y risk to the subject
Any laboratory  abnormalities that in th e judgment of the investigator prevents the subject 
from continuing participation in the study
A consecutive 3 -month interruption of study  treatment
If discontinuation of study  treatment occurs, the investigator should make a reason able effort 
to understand the primary reason for the subject’s premature discontinuation of study treatment 
and record this information.
Subjects who discontinue study  treatment or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLESS they  withdraw 
their consent (see withdraw of informed consent section,). 
The investigator must also contact the IRT to register the subject’s discontinuation from study  
treatment.
9.1.2 Withdrawal of informed consen t
Subjects may voluntarily  withdraw consent to participate in the study  for any reason at any time. 
Withdrawal of consent occurs onl y when a subject:
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information.
Study  treatment must be discontinued a nd no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact the subject are not allowed unless safety  findings require 
communicating or follow -up.

Novartis Confidential Page 49
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table.
Novarti s will continue to keep and use collected study  information (including any data resulting 
from the analy sis of a subject’s samples until the time of withdrawal) according to applicable 
law.
For the United States (US)and Japan: All biological samples not yet analy zed at the time of 
withdrawal may still be used for further testing/analy sis in accordance with the terms of this 
protocol and of the informed consent form.
For European Union ( EU)and Rest of Worl d (RoW ): All biological samples not yet analyzed 
at the time of withdrawal will no longer be used, unless permit ted b y applicable law. They will 
be stored according to applicable legal requirements.
9.1.3 Lost to follow -up
For subjects whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withdraw, the investigator must show "due diligence" by 
documenting in the source documents steps taken to contact the subject, e.g. dates of telephone 
calls, registered letters, etc. A subject should not be considered as lost to follow -up until due 
diligence has been completed or until the end of the study .
9.1.4 Early  study termination by  the sponsor
The study  can be terminated by  Novartis at any  time for any  reason. This may  include reasons 
related to the benefit/ risk assessment of participating in the study , practical reasons (including 
slow enrollment), or for regulatory  or medical reasons. In taking the decision to terminate, 
Novartis will alway s consider the subject welfare and safet y. Should early  termination be 
necessary , subjects must be seen as soon as possible (provide instruction for contacting the 
subject, when the subject should stop taking drug, when the subject should come for a final visit) 
and treated as a prematurely  withdrawn subject. The investigator may be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the 
protection of the subject’s interests. The investigator or sponsor depending on the local 
regulation will be responsible for informing IRBs/IECs of the early termination of the trial.
Reasons for earl y termination:
Unexpected, significant, or unacceptable safet y risk to subjects enrolled in the study
Decision based on recommendations from applicable board(s) after review of safet y and 
efficacy  data 
Discontinuation of study  drug development
The results of the PANORAMA- HF core study  do not support local registration
The investigator must provide follow -up medical care for all patients who are prematurely 
withdrawn from stud
y drug or refer them for appropriate ongoing care.

Novartis Confidential Page 50
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
9.2 Stud y completion and post -study  treatment
Study  completion is defined as when the last subject finishes their Study  Completion visit and 
any repeat assessments associated with this visit have been documented and followed -up 
appropriatel y by t he investigator or, in the event of an early  study termination decision, the date 
of that decision .
10 Safety  monitoring and reporting
10.1 Definition of a dverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The investigator has the responsibility  for managin g the safet y of individual subject and 
identify ing adverse events.
Novartis qualified medical personnel will be readily available to advise on trial -related medical 
questions or problems.
The occurrence of adverse events must be sought by non -directive que stioning of the subject at 
each visit during the study. Adverse events also may be detected when they are volunteered b y 
the subject during or between visits or through physical examination findings, laboratory  test 
findings, or other assessments.
Adverse events must be recorded under the signs, symptoms, or diagnosis associated with them, 
accompanied by the following information (as far as possible) (if the event is serious refer to 
Section 10.1.2):
1.The severit y grade
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
2.its relationship to the study  treatment and other 
investigational treatment. For example, i f 
the event is due to progression of the study  indication ,the assessment of causality  will 
usually  be ‘Not suspected.’ The rationale for this guidance is that progression of 
underly ing illness are not caused by  thetrial drug, they  happen in spite of its 
administration and can only  be evaluated meaningfull y by an anal ysis of cohorts, not on a 
single subject
3.its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must b e reported
4.whet her it constitutes an SAE (see Section 10.1.2 for definition of SAE) and which 
seriousness criteria have been met 

Novartis Confidential Page 51
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
5.action taken regarding with study  treatment
All adverse events must be treated appropriately . Treatment may include one or more of the 
following:
Study  drug dose not changed
Study  drug dose Reduced/increased
Study  drug interrupted/withdrawn
6.its outcome
Conditions that were alread y present at the time of informed consent should be recorded in 
medi cal history  of the subject.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued for at least 30 days following the last dose of 
study  treatment.
Once an adverse event is detected, it must be followed until its resolution or until it is judged to 
be permanent (e.g. continuing at the end of the study ), and assessment must be made at each 
visit (or more frequently , if necessary ) of any  changes in severit y, any potential relationship to 
the interventions required to treat it, and the outcome.
Information about adverse drug reactions for the investigational drug can be found in the 
Investigator ’sBrochure (IB).
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  significant
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to b e non -typical in subjects with 
the underl ying disease. Alert ranges for laboratory and other test abnormalities are included in 
Appendix 1 .
10.1.2 Serious adverse events
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] 
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the following 
criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the subject was a t risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (please refer to the I CH-E2D Guidelines).

Novartis Confidential Page 52
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for: 
a.routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition
b.elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
c.social reasons and respite care in the absence of any  deterioration in the subject’s 
general condition
d.treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospital admission
is medically  significant, e.g. defined as an event that jeopardizes the subject or may
require medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospitalization but might jeopardize the subject or might 
require intervention to prevent one of the other outcomes listed above. Such events should be 
considered as “medicall y significant”. Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospitalization or development of dependency  or abuse (please refer to the ICH-
E2D Guidelines).
Allmalignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met and the malignant neoplasm is not a disease progression of the 
study  indication .
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred.
10.1.3 SAE reporting
To ensure subject safet y, every SAE, regardless of causalit y, occurring after the subject has 
provided informed consent and until 30 days after the last study  visit must be reported to 
Novartis safet y immediately , without undue delay , but under no circumstances later than within
24 hours ofobtaining knowledge of the events (Note: If more stringent, local regulations 
regarding reporting timelines prevail) . Detailed instructions regarding the submission process 
and requirements are to be found in the investigator folder provided to each site.
SAEs occurring after the subject has provided informed consent until the time the subject is 
deemed a Screen Failure must be reported to Novartis.

Novartis Confidential Page 53
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Investigators will report events that are commonly  seen in the study  population, but they will 
not be reported as Suspected Unexpected Serious Adverse Reactions (SUSARs )to regulatory 
agencies, ethics committees (ECs), or investigators during the stud y (Table 10 -1).
Table 10
-1 E vents commonly  seen in study  population
Cardiovascular events Non-cardiovascular events 
Worsening HF Bronchitis Influenza 
Edem a Vomiting Nasopharyngitis 
Hypotension Cough Nausea 
Renal impairment Diarrhea Pneumonia 
Failure to thrive Upper respirator y infection 
Fatigue Weight change 
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
immediately , without undue delay , but under no circumstances later thanwithin 24 hours of the 
investigator receiving the follow -up information. (Note: If more stringent, local regulations 
regarding reporting timelines prevail) . An SAE occurring at a different time interval or 
otherwise considered completely  unrelated to a previously  reported one must be reported 
separately  as a new event.
If the SAE is not previously  documented in the Investigator’s Brochure (new occurrence) and 
is thought to be related to the study  treatment, a CMO & PS Department associate may urgentl y 
require further information from the investigator for health authorit y reporting. Novartis may 
need to issue an Investigator Notification (IN) to inform all investigators involved in an y stud y 
with the same study  treatment that this SAE has been reported.
SUSARs will be collected and reported to the competent authorities and 
relevant ethics 
committees in accordance with EU Guidance 2011/C 172/01 , Food Drug Administration (FDA )
Guidance 2012 or as per national regulatory  requirements in participating countries.
Any SAEs experienced after the 30-day period following end of study  visit should only be 
reported to Novartis Safety  if the investigator suspects a causal relationship to study  treatment.
10.1.4 Pregnancy  reporting
Pregnancies
Should a pregnancy be discovered during the course of study , the following procedure must be 
followed. In case of pregnancy  discovered during the screening period , the patient will be 
withdrawn from the study immediatel y.
To ensure patient safet y, each preg nancy  occurring after signing the informed consent must be 
reported to Novartis within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.

Novartis Confidential Page 54
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Pregnancy  should be recorded and reported by the investigator to the Novartis Chief Medical 
Office and Patient Safety  (CMO&PS). Pregnancy  follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to study  treatment any 
pregnancy  outcome.
Any SAE experienced during the pregnancy  and unrelated to the pregnancy  must be reported 
on a SAE form.
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, subject or 
consumer [Europea n Medicines Agency  (EMA) definition ].
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied by harmful physical or psychological effects. Please refer to the 
Guidance for capturing the study  treatment errors including misuse/abuse in Table 10
-2.
Study  treatment errors a nd uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to 
Safety  only if associated with an SAE. Misuse or abuse will be collected and reported in the 
safet y database irrespective of it being associated with an AE/SAE within 24 hours of 
investigator’s awareness.
Table 10-2 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error type Document in Dosing 
CRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated 
with an AEOnly if associated with 
an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.
10.2 Additional Safety  Monitoring
10.2.1 Liver safety monitoring
To ensure subject safety  and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.
The following two categories of abnormalities / adverse events have to be considered during 
the cours e of the study  (irrespective of whether classified/reported as AE/SAE):
Liver laboratory  triggers, which will require repeated assessments of the abnormal 
laboratory  parameter

Novartis Confidential Page 55
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Liver events, which will require close observation, follow- up monitoring and con tributing 
factors are recorded on the appropriate CRFs
Please refer to Table 16-3 in Appendix 2for complete definitions of liver laboratory  triggers 
and liver events.
Every  liver event defined in Table 16-3should be followed up by the investigator or designated 
personnel at the trial site, as summarized below. Additional details on actio ns required in case 
of liver events are outlined in Table 16-4. Repeat liver chemistry  tests (i.e. ALT, AST, Albumin, 
TBL, PT/INR, ALP and GGT) to confirm elevation.
These liver chemistry  repeats should be performed using the local laboratory  used by  the 
site. Repeated laboratory  test results must be reported as appropriate.If the initial elevation 
is confirmed, close observation of the subject will be initiated, including consideration of 
treatment interruption if deemed appropriate.
Discontinuation of the investigatio nal drug (refer to the Discontinuation of study treatment 
section), if appropriate
Hospitalization of the subject if appropriate
Causality  assessment of the liver event
Thorough follow -up of the liver event should be performed and evaluations may  include 
additional investigations:
These investigations can include based on investigator’s discretion: serology tests, 
imaging and pathology  assessments, hepatologist’s consultancy ; obtaining more 
detailed history  of sy mptoms and prior or concurrent diseases, history  of concomitant 
drug use, exclusion of underly ing liver disease
All follow -up information and procedures performed must be recorded as appropriate in the 
CRF.
Follow up on potential drug -induced liver injury (DILI) cases
Subjects with transaminase increase combined with TBL increase may be indicative of potential 
DILI and should be considered as clinically  important events.
The threshold for potential DILI may depend on the subject’s baseline AST/AL T and TBL 
value; subjects meeting any of the followi ng criteria will require further follow -up as outlined 
below:
For subjects with normal AL T and AST and TBL value at baseline: AST or AL T > 3.0 x 
ULN combined with TBIL > 2.0 x UL N
For subjects with elevated AST or ALT or TBIL value at baseline: [AST or AL T> 2 x 
baseline AND > 3.0 x ULN] OR [AST or AL T > 8.0 x ULN], combined with [TBL  > 2 x 
baseline AND > 2.0 x ULN]
Medical review needs to ensure that liver test elevations are not caused by  cholestasis, defined 
as ALP elevation > 2.0 x ULN with R value < 2 in subjects without bone metastasis, or elevation 
of AL P liver fraction in subjects with bone metastasis.

Novartis Confidential Page 56
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Note: The R value is calculated by  dividing the ALT by  the AL P, using multiples of the ULN 
for both values. It denotes whether the relative pattern ofALT and/or ALP elevation is due to 
cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R > 2 and < 5) liver injury .
In the absence of cholestasis, these subjects should be immediately  discontinued from study 
treatment, and repeat Liver Function Tests ( LFT)testing as soon as possible, preferabl y within 
48 hours from the awareness of the abnormal results. The evaluation should include laboratory 
tests, detailed history , phy sical assessment, and the possibility  of liver metastasis or new liver 
lesions, obstructions/compressions, etc.
Laboratory  tests should include ALT, AST, albumin, creatine kinase, total bilirubin, direct 
and indirect bilirubin, GGT, prothrombin time (PT)/INR, and alkaline phosphatase.
A detailed history , including relevant information, such as review of ethanol , concomitant 
medications, herbal remedies, supplement consumption, and history  of an y pre-existing 
liver conditions or risk factors, should be collected.
Further testing for acute hepatitis A, B, C or E infection and liver imaging (e.g. biliary  
tract) may  be warranted.

Additional testing for other hepatotropic viral infection [Epstein- Barr virus (EBV ), 
cytomegalovirus (CMV ), or herpes simplex virus ( HSV )], autoimmune hepatitis or liver 
biopsy  may  be considered as clinically  indica ted or after consultation with 
specialist/hepatologist.
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified, should be considered as “medicall y 
significant,” and thus, meet the definition of a serious adverse event (SAE) and should reported 
as SAE using the term “potential drug -induced liver injury .” All events should be followed up 
with the outcome clearly  documented.
10.2.2 Renal safety  monitoring
Every  renal labor atory  trigger or renal event as defined in Table 16-5 should be followed up by 
the investigator or designated personnel at the trial site as s
ummarized in Appendix 3.
10.2.3 Angioedema Adjudication committee
If an angioedema or angioedema -like event occurs, the investigator will complete an 
Adjudication Questionnaire for an Angioedema -like Event form (provided by Novartis). Details 
on the process of reporting angioedema and angioedema -like events are outlined in a manual 
provided to investigators.
Submission of an angioedema report is not a substitution for the submission of an SAE report. 
If an angioedema -like event satisfies the definition of an SAE, the investigator must submit an 
SAE report in addition to the Adjudication Questionnaire for an Angioedema -like Event.
The membership and responsibilities of the Angioedema Adjudication 
Committee are defined 
in a separate document that will be provided to the sites.

Novartis Confidential Page 57
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
11 Data collection and database management
11.1 Data collection
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.
Designated investigator staff will enter the data required by the protocol into the Electronic 
Case Report Forms (eCRF). The eCRFs have been built using fully validated secure web-
enabled software that conforms to 21 CFR Part 11 requirements, investigator site staff will not 
be given access to the Electronic Data Capture (EDC )system until they have been trained. 
Automatic validation programs check for data discrepancies in the eCRFs, allow modification 
and/or verification of the entered data b y the investigator staff.
The investigator/designee is responsible for assuring that the data (rec orded on CRFs) (entered 
into eCRF) is complete, accurate, and that entry  and updates are performed in a timely  manner. 
The investigator must certify  that the data entered are complete and accurate
After final database lock, the investigator will receive copies of the subject data for archiving 
at the investigational site.
11.2 Database management and quality  control
Novartis personnel [ or designated Clinical Research Organization ( CRO) ]will review the data 
entered by investigational staff for completeness and accuracy . Electronic data queries stating 
the nature of the problem and requesting clarification will be created for discrepancies and 
missing values and sent to the investigational site via the EDC s ystem. Designated investigator 
site staff members are required to respond promptly  to queries and to make any necessary 
changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
World Health Organization (WHO )Drug Reference List, which employ s the Anatom ical 
Therapeutic Chemical classification system. Medical history /current medical conditions and 
adverse events will be coded using the Medical Dictionary  for Regulatory  Activities (MedDRA) 
terminology .
Data about all study  treatment (s) dispensed to the subject and all dosage changes will be tracked 
using an Interactive Response Technology  (IRT). The system will be supplied by a vendor, who 
will also manage the database. The data will be sent electronically  to Novartis (or a designated 
CRO) at specific time lines.
Once the database has been declared to be complete and accurate, it will be locked and made 
available for data analysis. Any  changes to the database after that time can only be made after 
written agreement b y Novartis development management.
11.3 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a 
Novartis/delegated CRO representative will review the protocol and data capture requirements 
(i.e. eCRFs) with the investigators and their staff. During the study, Novartis employ s several 
methods of ensuring protocol and GCP compliance and the quality /integrity  of the sites’ data. 

Novartis Confidential Page 58
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
The field monitor will visit the site to check the completeness of subject records, the accuracy 
of data capture / data entry , the adherence to the protocol and to Good Clinical Practice, the 
progress of enrollment, and to ensure that study treatment is being stored, dispensed, and 
accounted for according to specifications. Key study personnel must be available to assist the 
field monitor during these visits. Continuous remote monitoring of each site’s data may be 
performed by a  c entralized Novartis/ delegated CRO /Clinical Research Associate (CRA )
organization. Additionally, a central analytics organization may analyze data & identify  risks 
& trends for site operational parameters, and provide reports to Novartis /sponsor clinical teams 
to assist with trial oversight.
The investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospita l or clinic medical records) containing demographic and medical 
information, laboratory  data, and the results of any  other tests or assessments. All information 
on CRFs must be traceable to these source documents in the subject’s file.The investigator 
must also keep the original informed consent form signed by the subject (a signed cop y is given  
to the subject).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entr y. Novartis monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. Additional 
checks of the consist ency  of the source data with the CRFs are performed according to the 
study -specific monitoring plan. No information in source documents about the identity  of the 
subjects will be disclosed.
12 Data analy sis and statistical methods
Any data analy sis carried out independently  b y the investigator should be submitted to Novartis 
before publication or presentation.
12.1 Analysis sets
The following anal ysis sets will be used for the statistical anal yses:
Screened set (SCR): All patients who signed the informed consent for the extension open -
label study .
Safety  Set (SAF): All SCR patients who received at least one dose of open -label study  
treatment during the extension open -label study .
12.2 Subject demographics and other baseline characteristics
In the following, the term “a ge group” refers to the two age groups. Summary  statistics will be 
provided b y age group (6 years and older, 1 year to < 6 years) and for overall for demographics 
and baseline characteristics, including age, age group (only for overall), sex, race, ethnici ty, 
weight, height andvital signs.
Continuous variables will be summarized using n, mean, standard deviation, median, minimum, 
and maximum. Categorical variables will be summarized using frequencies and percentages.

Novartis Confidential Page 59
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Relevant medical histories will be summ arized, by system organ class and preferred term, for 
overall and for each age group .
The SAF will be used for the above anal yses.
12.3 Treatments
Duration of exposure to the study  treatment will be summarized for each age group and for 
overall, using mean, standard deviation, median, minimum, and maximum. Additionally , the 
number and percentage of patients in meaningful duration categories will be summarized for 
each age group and for overall . 
Concomitant medications and signific ant non-drug therapies prior to and after the start of the 
study  treatment will be summarized by anatomical therapeutic classification (ATC), preferred 
term, for overall and for each age group.
The SAF will be used for the above anal yses.
12.4 Analysis of the p rimary  endpoint(s)
The primary  objective is to evaluate safet y and tolerability  of LCZ696 in eligible heart failure 
patients from PANORAMA -HF receiving open -label investigational drug.
The primary  safety assessment will be based on adverse events, which will be analy zed using 
frequencies and percentages.
The following adverse events will be summarized by primary  system organ class, preferred 
term, and maximum severity  as appropriate, for each age group and for overall, using numbers 
and percentages of patie nts with at least one adverse event in the corresponding class.
Any adverse event (treatment emergent or not)
Any serious adverse event (treatment emergent or not)
Treatment emergent adverse event (TEAE)
Treatment emergent serious adverse event
Treatment e mergent adverse event of special interest, i.e. hy perkalemia, h ypotension, 
angioedema, renal impairment
TEAE leading to dose adjustment, temporary  dose interruption, or permanent 
discontinuation (including death) of stud y treatment
TEAE leading to permanent discontinuation (including death) of stud y treatment
For overall and for each age group, death during the treatment period and the primary  cause of 
death will be summarized using frequencies and percentages.
For overall and for each age group, the vital signs and the laboratory  evaluations will be 
summarized by  visit.
Adverse events (including SAEs) , laboratory  assessments, vital signs, and duration of drug 
exposure are considered primary  endpoints.

Novartis Confidential Page 60
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
12.4.1 Definition of primary  endpoint(s) 
Adverse events, laboratory  assessments, vital signs, and duration of drug exposure are 
considered primary  endpoints.
12.5 Analysis of secondary  endpoints
Not applicable. There are no secondary  endpoints.
12.6 Analysis of exploratory  endpoints
Not applicable. There a re no exploratory  endpoints.
12.7 Interim analy ses
No interim analysis is planned. However, the safety  will be monitored through regular review 
of adverse events and related data.
12.8 Sample size calculation
12.8.1 Primary  endpoint(s)
All patients who have completed the double -blind phase of the study  PANORAMA -HF,as 
defined in the Inclusion Criteria (Section 5.1 ),and who meet all other I nclusion and Exclusion 
criteria ( Section 5.1and Section 5.2), are eligible for the extension study .
There is no specific sample size required for the study .
12.8.2 Secondary  endpoint(s)
Not applicable.
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki.
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion from 
the Institutional Review Board/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
written informed consent form, consent form updates, subject recruitment procedures (e.g. 
advertisements) and any other written information to be provided to subjects. Prior to study 
start, the investigator is required to sign a protocol signature page confirming his/her agreement 
to conduct the study  in accordance with these documents and all of the instructions and 
procedures found in this protocol and to give access to all relevant data and records to 
Novartis /sponsor monitors, auditors, Novartis /sponsor Quality  Assurance representatives, 

Novartis Confidential Page 61
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
designated agents of Novartis /sponsor , IRBs/IECs, and regulatory  authorities as required. If an 
inspection of the clinical site is requested by a regulatory  authorit y, the investigator must inform 
Novartis/ sponsor immediately  that this request has been made.
13.3 Publication of study  protocol and results
The protocol will be registered in a publicly  accessible database such as clinicaltrials.gov and 
as required in EudraCT. In addition, after study  completion (defined as last patient last visit) 
and finalization of the study report the results of this trial will be submitted for publication and 
posted in a publicly  accessible databas e of clinical trial results, such as the Novartis clinical trial 
results website and all required Health Authority  websites (e.g. Clinicaltrials.gov, EudraCT 
etc.).
For details on the Novartis publication policy  including authorship criteria, please refer to the 
Novartis publication policy training materials that were provided to you at the trial investigator 
meetings.
13.4 Qualit y Control and Quality  Assurance
Novartis maintains a robust Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and I CH Guidelines.
Audits of investigator sites, vendors, and Novartis systems are performed by auditors, 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk- based approach.
Audits are conducted to assess GCP compliance with global and local regulat ory requirements, 
protocols and internal Standard Operating Procedures (
SOPs) , and are performed according to 
written 
Novartis processes.
14 Protocol adherence
This protocol defines the study  objectives, the study procedures and the data to be collected on 
study  participants. Additional assessments required to ensure safety  of subjects should be 
administered as deemed necessary  on a case by case basis. Under no circumstances including 
incidental collection is an investigator allowed to collect additional data or conduct any 
additional procedures for any purpose involving any investigational drugs under the protocol, 
other than the purpose of the study . If despite this interdiction prohibition, data, information, 
observation would be incidentally  collected, the investigator shall immediately  disclose it to 
Novartis and not use it for any purpose other than the study , except for the appropriate 
monitoring on study  participants.
Investigators ascertain they will apply due diligence to avoid protocol deviations. I f an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis
and approved by the IR B/IEC and health authorities, where required, itcannot be implemented.

Novartis Confidential Page 62
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
14.1 Protocol amendments
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis , health authorities where required, and the IRB/IEC prior to 
implementation.
Only  amendmen ts that are required for subject safet y may be implemented immediately 
provided the health authorities are subsequently  notified by protocol amendment and the 
reviewing IRB/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, Novartis should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local regulations.

Novartis Confidential Page 63
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
15 References
References are available upon request
Andrews RE, Fenton MJ, Ridout A, et al. (2008) New onset heart failure due to heart muscle 
disease in childhood: A prospective stud y in the United Kingdom and Ireland. Circulation; 
117:79 -84.
CVAL 489K2304 (2011) Phy sician survey  of clinical management and uses of medicinal 
products in paediatric patients with heart failure survey protocol. Diovan pediatric heart 
failure survey . Novartis Internal Document.
Howie SR (2011) Blood sample volumes in child health research: review of safe limits. Bull 
World Health Organ; 89:46-53.
Hsu DT, Pearson GD (2009) Heart failure in children Part I: History , etiology  and 
pathophy siology . Circulation Heart Failure; 2:63-70.
Kantor PF, Mertens LL (2010) Clinical practice: Heart failure in children. Part II : current 
maintenance therap y and new therapeutic approaches. Eur J Pediatr; 169:403-410.
Kleinman ME, Chameides L , Schexnay der SM, et al. (2010) Part 14: PALS (Pediatric 
Advanced Life Support): 2010 American Heart Association guidelines for cardiopulmonary  
resuscitation and emergency  cardiovascular care. Circulation; 122:S876 -S908.
Mah D, Singh TP, Thiagarajan RR, et al. (2009) Incidence and risk factors fo r mortality  in 
infants awaiting heart transplantation in the USA. J Heart L ung Transplant; 12: 1292 -8.
McMurray  JJV, Packer M, Akshay  S, et al. (2014) Angiotensin -nepril ysin inhibition versus 
enalapril in heart failure. N Engl J Med; 371(11):993 -1004.
Peters A, Gordon I (1999) Quantitative Assessment of the Urinary  Tract with Radionuclides. 
In Barratt T. M, Avner E, Harmon W (eds), Pediatric Nephrology , fourth edition, pp 365-735. 
Lippincott Williams & Wilkins, Mary land.
Sharma M, Nair M, Jatana SK, et al. (2003) Congestive heart failure in infants and children. 
MJAFI ; 59:228 -233.
Schwartz GJ, Work DF (2009) Measurement and estimation of GFR in children and 
adolescents. Clin J Am Soc Nephrol; 4:1832 –1843.

Novartis Confidential Page 64
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
16 Appendices
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs
Table 16-1 Clinically  notable laboratory  values
Parameter Conventional
Alert ValueConventional
UnitsSI Alert
ValueSI
Units
Hematology
Red Blood Cell 
Count >50% 
increase, >30% 
decreasex10E6/uL >50% 
increase, >30% 
decreasex10E12/L
Hemoglobin >50% 
increase, >30% 
decrease, or any 
value <7g/dL >50% 
increase, >30% 
decrease, or any 
value <70g/L
Hematocrit >50% 
increase, >30% 
decrease% >50% 
increase, >30% 
decreaseL/L
White Blood Cell 
Count >50% 
increase, >50% 
decreasex10E3/uL >50% 
increase, >50% 
decreasex10E9/L
Platelet Count >75% 
increase, >50% 
decreasex10E3/uL >75% 
increase, >50% 
decreasex10E9/L
Chemistry
BUN >50% increase mg/dL >50% increase mmol/L
Creatinine >50% increase mg/dL >50% increase umol/L
Albumin <2 g/dL <20 g/L
Glucose >50% 
increase, >50% 
decrease, or any 
value <60mg/dL >50% 
increase, >50% 
decrease, or any 
value <3.3mmol/L
Total Bilirubin >100% increase mg/dL >100% increase umol/L
AST (SGOT) >150% increase U/L >150% increase U/L
ALT (SGPT) >150% increase U/L >150% increase U/L
Sodium >5% increase, or 
any value >150mEq/L >5% increase, or 
any value >150mmol/L
Potassium >20% 
increase, >20% 
decrease, or any 
value >5.3 mEq/L >20% 
increase, >20% 
decrease, or any 
value >5.3 mmol/L
Chloride >10% 
increase, >10% 
decreasemEq/L >10% 
increase, >10% 
decreasemmol/L
Calcium >10% 
increase, >10% 
decreasemg/dL >10% 
increase, >10% 
decreasemmol/L
Uric Acid >50% increase mg/dL >50% increase mmol/L

Novartis Confidential Page 65
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Table 16-2 Criteria for clinically  notable vital signs
Age HR [min-1] SBP [mmHg] DBP [mmHg] RR [min-1]
1-3 years <60, >120 <76, >115 <45, >75 <14, >35
3-6 years <55, >120 <82, >120 <50, >80 <12, >30
6-12 years <50, >105 <90, >130 <50, >80 <10, >27
>12 years <45, >95 <90, >145 <55, >90 <8, >23

Novartis Confidential Page 66
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
16.2 Appendix 2: Liver event and laboratory trigger definitions and 
follow -up requirements
Table 16-3 Liver event and laboratory  trigger definitions
Definition/ threshold
LIVER LABORATORY TRIGGERS 3 ×ULN < ALT / AST ≤5 ×ULN
1.5 ×ULN < TBL ≤2 ×ULN
LIVER EVENTS ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBL > 2 × ULN (in the absence of known Gilbert 
syndrome)
ALT or AST > 3 × ULN and INR > 1.5 
Potential Hy’s Law cases (defined as ALT or AST > 3 × 
ULN and TBL > 2 × ULN [mainly conjugated fraction] 
without notable increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) malaise, 
fatigue, abdominal pain, nausea, or vo miting, or rash 
with eosinophilia
Any adverse event potentially indicative of a liver toxicity*
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -
related conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver 
neoplasms
TBL: total bilirubin; ULN: upper limit of normal 
Table 16-4 Follo w-up requirements for liver events and laboratory  trigger s
Criteria Actions required Follow -up monitoring
Potential Hy’s 
Law caseaDiscontinue the study treatment 
immediately
Hospitalize, if clinically 
appropriate
Establish causality
Complete liver eCRFALT, AST, TBL, Albumin ( Alb), 
PT/INR, ALP and γGT until 
resolutionc(frequency at 
investigator discretion)
ALT or A ST
> 8 × ULN Discontinue the study treatment 
immediately
Hospitalize if clinically 
appropriate
Establish causality
Complete liver eCRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
> 3 × ULN and 
INR > 1.5Discontinue the study treatment 
immediately
Hospitalize, if clinically 
appropriate
Establish causality
Complete liver eCRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)

Novartis Confidential Page 67
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Criteria Actions required Follow -up monitoring
> 5 to ≤ 8 × ULN Repeat LFT within 48 hours
If elevation persists, continue 
follow -up monitoring
If elevation persists for more 
than 2 weeks, discontinue the 
study drug
Establish causality
Complete liver eCRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
> 3 × ULN 
accompanied by 
symptomsbDiscontinue the study treatment 
immediately
Hospitalize if clinically 
appropriate
Establish causality
Complete liver eCRFALT, AST, TBL, A lb, PT/INR, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
> 3 to ≤ 5 × ULN 
(patient is 
asymptomatic)Repeat LFT within the next 
week
If elevation is confirmed, initiate 
close observation of the patientInvestigator discretion
Monitor LFT within 1 to 4 weeks 
ALP (isolated)
> 2 × ULN (in the 
absence of known 
bone pathology)Repeat LFT within 48 hours
If elevation persists, establish 
causality
Complete liver eCRFInvestigator discretion
Monitor LFT within 1 to 4 weeks or 
at next visit
TBL (isolated)
> 2 × ULN (in the 
absence of known 
Gilbert syndrome)Repeat LFT within 48 hours
If elevation persists, discontinue 
the study drug immediately
Hospitalize if clinically 
appropriate
Establish causality
Complete liver eCRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
Test for hemoly sis (e.g. 
reticulocytes, haptoglobin, 
unconjugated [indirect] bilirubin)
> 1.5 to ≤ 2 × ULN 
(patient is 
asymptomatic)Repeat LFT within the next 
week
If elevation is confirmed, initiate 
close observation of the patient Investigator discretion
Monitor LFT within 1 to 4 weeks or 
at next visit
Jaundice Discontinue the study treatment 
immediately
Hospitalize the patient
Establish causality
Complete l iver eCRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
Any AE potentially 
indicative of a 
liver toxicityConsider study treatment 
interruption or discontinuation 
Hospitalization if clinically 
appropriate
Establish causalityInvestigator discretion

Novartis Confidential Page 68
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Criteria Actions required Follow -up monitoring
Complete liver eCRF
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosin ophilia 
cResolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable 
values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level 
after a maximum of 6 months, (4) liver transp lantation, and (5) death.

Novartis Confidential Page 69
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
16.3 Appendix 3: Specific renal alert criteria and actions
Table 16-5 Specific renal alert criteria and actions
Serum event
Estimated GFR* decrease
≥ 25% compared to baseline AND eGFR  
< 90 mL/min/1.73m2 Confirm ≥ 25% decrease AND eGFR*
< 90 mL/min/1.73m2after 24 -48 hours (h). 
If it persists, follow up with repeat, if possible, 
within 2 -5 days. 
Then do some frequent monitoring (preferably 
weekly ) until event resolves or stabilizes. 
If event does not resolve or stabilize, consider 
consulting nephrologist and/or drug interruption.
Acute Kidney Injury: Serum estimated GFR* 
decrease ≥50% compared to baseline in the 
PANORAMA -HF core study (i.e. Visit 301 for Part 
2)Follow up within 24 -48h if possible.
If value persists, consider consulting nephrologist 
and/or drug interruption.
Urine event Confirm by  urinar y protein creatinine ratio. 
If it persists, consider consulting nephrologist 
and/or drug interruption.
New dipstick proteinuria ≥ 1+ Confirm value after 24- 48 h, if possible.
If dipstick value confirmed: 
a) perform urinary protein /creatinine ratio (PCR) 
within 2 -5 days, if possible. If PCR > 0.2 then:
b) perform urine microscopy and evaluate.
If PCR > 0.2 and /or urine microscopy has 
findings (e.g. crystals, casts, dysmorphic RBC, 
leukocytes), consider consulting nephrologist or 
drug interruption or discontinuation
New dipstick glucosuria ≥ 1+ not due to diabetes Confirm value after 24- 48 h, if possible.
If it persists: 
a) perform, blood glucose (fasting)
b) perform urinary protein/creatinine ratio. 
If PCR ratio > 0.2 and blood glucose abnormal 
consider consulting nephrologist and /or drug 
interruption or discontinuation
New dipstick hematuria ≥ 1+ not due to trauma Confirm value after 24- 48 h, if possible.
If it persists:
a) perform urinary protein creatinine ratio (PCR) 
within 2 -5 days on a first morning urine collection 
b) perform urine microscopy and evaluate.
If PCR > 0.2 and /or urine microscopy has 
findings (e.g. crystals, casts , dysmorphic RBC, 
leukocytes) consider consulting nephrologist or 
drug interruption or discontinuation
* eGFR is calculated using a modified Schwartz formula for subjects <18 years: 
eGFR (ml/min/1.73m2) = 0.413 x height (cm) / serum creatinine (mg/dl). The most recently available 
height should be used for calculation.

Novartis Confidential Page 70
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Urine samples for testing for renal monitoring, and particularly those for the PCR ratio determination, 
must be collected at the first morning void.
Document contributing factors in the eCRF: co -medication, other co -morbid conditions, and additional 
diagnostic procedures performed. 
Monitor patient regularly (frequency at invest igator’s discretion) until either: 
Event resolution: estimated GFR within 20% of baseline and > 90 mL/min/1.73m2or PCR < 0.2; 
Event stabilization: estimated GFR within 20% of baseline OR > 90 mL/min/1.73m2or PCR < 0.3.
Table 16-6 GFR by  age for initiation/up -titration and exclusion criteria
Age range* ≥ 30% mean GFR for 
age ( mL/min/1.73m2)**< 30% mean GFR for 
age ( mL/min/1.73m2)***
12 months to < 19 months (1 year, 7 months) ≥ 31 < 31
19 months to < 18 years ≥ 38 < 38
≥ 18 years ≥ 30 < 30
* Age rounded to nearest whole number
** Initiation/up -titration criteria
*** Exclusion criteria
Source: ( Peters and Gordon 1999 )

Novartis Confidential Page 71
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
16.4 Appendix 4: Guidelines for the management of renal dy sfunction
General principles:
Glomerular filtration rate in HF patients depends on intrinsic renal function and on a balance 
between afferent and efferent glomerular arterial tonicity . This tonicity  is partly  regulated by  a 
stimulation of angiotensin II and could be affected by  either study  medication. Moreover, renal 
dysfunction may develop or may deteriorate in some patients after study  drug administration. 
These recommendations have been developed to guide the investigators in managing patients 
with renal d ysfunction after OLE enroll ment and the first OL dose of LCZ696.
Two ty pes of response to serum creatinine increase are described:
Surveillance situation
If, at any time after OLE enrollment and the first open -label dose of LCZ696, eGFR%* 
decreases by ≥ 50% from baseline in the PANORAMA -HF core study  (i.e. Visit 301 for Part 
2), the i nvestigator will check for potentially  reversible causes of renal dy sfunction such as:
non-steroidal anti-inflammatory  drug intake, antibiotics, or other treatments known to cause 
creatininemi a
volume decrease, including that resulting from excessive dosing of diuretics
urinary  infection
urinary  tract obstruction
study  medication
Action situation
If a patient eGFR* decreases by ≥ 50% from baseline of the core study  (i.e. 
Visit 301 for Part 
2) (or if serum creatinine concentration rises above 3 mg/dL (265 μmol/L), the investigator will 
check for potentially  reversible causes of renal dysfunction (see above). If the investigator 
judges that study  medication has to be stopped, he/she will have to contact the Novartis medical 
monitor or his/her designee. Thereafter, serum creatinine assessments will have to be repeated 
at least each week until levels return to acceptable values. If study  medication was stopped, 
every  effort will be done to restart it again, according to clinical conditions.
*eGFR is calculated using a modified Schwartz formula for subjects <18 years.
For subjects ≥18 years, an adult formula for eGFR will be utilized (Reference: Novartis 
Nephrology  Guidance document)

Novartis Confidential Page 72
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
16.5 Appendix 5 : American heart association (A HA) pediatric 
advanced life support (PA LS) guidelines
Table 16-7 5thpercentile sy stolic blood pressure (SBP) table
Age SBP percentile SBP (mmHg)
1 month to < 1 year 5th70
1 year 5th72
2 years 5th74
3 years 5th76
4 years 5th78
5 years 5th80
6 years 5th82
7 years 5th84
8 years 5th86
9 years 5th88
10 years 5th90
11 years 5th90
12 years 5th90
13 years 5th90
14 years 5th90
15 years 5th90
16 years 5th90
17 years 5th90
* AHA PALS guidelines 2010 ( Kleinman et al 2010 ) are widely used criteria for hypotension in acute 
HF patients. The formula (for 1 year and older: 70 mmHg + 2 x Age, up to age 10) is understood to 
provide the 5thSBP percentile up to 10 years. For children 1 month to < 1 year and >10 years, the 
AHA PALS guidelines 2010 5th percentile is set at 70 mmHg and 90 mmHg respectively. NOTE: 

Novartis Confidential Page 73
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
This formula approximates the population- based 5th percentile BP data; however, the margin of 
error increases with increasing age, with the PALS formula value generally providing a lower value.

Novartis Confidential Page 74
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
16.6 Appendix 6: Guideline s for the management of blood pressure
1.Investigator should monitor blood pressure closely.
2.If symptomatic hy potension occurs:
Correct an y treatable cause, e.g. h ypovolemia
If hypotension persists, any antih ypertensive drug and non -disease -modify ing drugs, 
such as diuretics, calcium channel blockers (CCBs), nitrates, and α -blockers, should 
be down -titrated or stopped first before down- titration of the study  drug is considered
If hypotension persists, the study drug should be down titrated or even temporarily
withdrawn.

Novartis Confidential Page 75
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
16.7 Appendix 7 : Treatment guidelines for elevated potassium and 
hyperkalemia (serum potassium ≥5.3 mmol/L)
General principles
Elevation of potassium levels on a non-hemolyzed specimen above the predefined values 
should be repeated and confirmed before any action, if appropriate based on 
investigator’s 
medical judgment.
For assessment of potassium, no blood sample should be drawn by finger or heel stick. Also 
note that pH can affect potassium values, and that abnormal potassium values should include
assessment of pH. Each 0.1 increase in pH represents a 0.6 mEq/L  change in the opposite 
direction of the pH change.
Patients with elevated potassium value will be managed according to the corrective actions 
outlined below. Hy perkalemia should be followed until resolution.
Corrective action for management of elevated potassium and hyperkalemia
Serum potassium > 5.2 and ≤5.4 mmol/L
Confirm potassium concentration in a non -hemoly zed sample.
Reinforce low potassium diet and restriction of food/drinks with high potassium content (e.g. 
orange juice, melon, bananas, low-salt substitutes etc.).
Review medical regimen (including dietary supplements and over -the-counter medications) for 
agents known to cause hyperkalemia. Consider reduction in dose or discontinuation of these 
agents:
Aldosterone antagonists (if they  are believed to be the most likely  cause of hy perkalemia)
Potassium -sparing diuretics (e.g. amiloride and triamterene) including in combination 
products with thiazide or loop diuretics
Potassium supplement s, e.g. potassium chloride
Salt substitutes
Non-steroidal anti -inflammatory  drugs (NSAIDs)
Cyclo-oxygenase -2 (COX -2) inhibitors
Trimethoprim and trimethoprim -containing combination products, such as Bactrim® and 
Septra® (trimethoprim/sulfamethoxazole fixed combination)
Herbal Supplements: For example, Noni juice, alfalfa ( Medicago sativa ), dandelion 
(Taraxacum officinale ), horsetail ( Equisetum arvense ), nettle ( Urtica dioica ), milkweed, 
lilyof the valley , Siberian ginseng, hawthorn berries.
Repeat serum potassium measurement within 3 to 5 days. If serum potassium remains > 5.2 and 
≤ 5.4 mmol/L , regularl y monitor serum potassium levels to ensure stability  suggested once 
monthly .
Consider down
-titration of study  medication, according to investigator’s medical judgment.

Novartis Confidential Page 76
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
Serum potassium > 5.4 and < 6.0 mmol/L
Confirm potassium concentration in a non -hemoly zed sample.
Consider down -titration or temporarily  discontinue study  drug according to investigator 
medical judgment.
Apply  all measures outlined for serum potassium > 5.2 and ≤ 5.4 mmol/L .
Repeat serum potassium measurement after 2 -3 day s.
If serum potassium < 5.4 mmol/L , consider resumption of study  drug at lower dose with 
repeat potassium within 5 day s.
Serum potassium ≥6.0 mmol/L
Confirm potassium concen tration in a non -hemoly zed sample.
Urgently  evaluate patient and treat hy perkalemia as clinically  indicated.
Apply  all measures outlined for serum potassium > 5.4 and < 6.0 mmol/L .
Study  drug should be immediately interrupted or discontinued if the serum p otassium is greater 
than or equal to 6.0 mmol/L .
No resumption of study  drug without individualized case discussion with and permission from 
Novartis medical monitor or his/her designee.

Novartis Confidential Page 77
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
16.8 Appendix 8: Reference table – blood volume by  weight
Table 16-8 Reference table –blood collection volumes by body w eight (kg)
2.5% and 5% Blood volume table by weight (up to 35 kg)1
Body 
Weight 
(Kg)Total blood 
volume of the 
patient (mL)Maximum allowable volume 
(mL) in one blood draw 
(= 2.5% of total blood volume 
of the patient)Total maximum volume (mL) 
drawn in a 28 -day period 
( = 5% of total blood volume 
of the patient)
2.5 200 5 10
3 240 6 12
3.5 280 7 14
4 320 8 16
4.5 360 9 18
5 400 10 20
5.5 440 11 22
6 480 12 24
6.5 520 13 26
7 560 14 28
7.5 600 15 30
8 640 16 32
8.5 680 17 34
9 720 18 36
9.5 760 19 38
10 800 20 40
10.5 840 21 42
11 880 22 44
11.5 920 23 46
12 960 24 48
12.5 1000 25 50
13 1040 26 52
13.5 1080 27 54
14 1120 28 56
14.5 1160 29 58
15 1200 30 60
15.5 1240 31 62
16 1280 32 64
16.5 1320 33 66
17 1360 34 68
17.5 1400 35 70
18 1440 36 72
18.5 1480 37 74
19 1520 38 76
19.5 1560 39 78

Novartis Confidential Page 78
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
2.5% and 5% Blood volume table by weight (up to 35 kg)1
Body 
Weight 
(Kg)Total blood 
volume of the 
patient (mL)Maximum allowable volume 
(mL) in one blood draw 
(= 2.5% of total blood volume 
of the patient)Total maximum volume (mL) 
drawn in a 28 -day period 
( = 5% of total blood volume 
of the patient)
20 1600 40 80
20.5 1640 41 82
21 1680 42 84
21.5 1720 43 86
22 1760 44 88
22.5 1800 45 90
23 1840 46 92
23.5 1880 47 94
24 1920 48 96
24.5 1960 49 98
25 2000 50 100
25.5 2040 51 102
26 2080 52 104
26.5 2120 53 106
27 2160 54 108
27.5 2200 55 110
28 2240 56 112
28.5 2280 57 114
29 2320 58 116
29.5 2360 59 118
30 2400 60 120
30.5 2440 61 122
31 2480 62 124
31.5 2520 63 126
32 2560 64 128
32.5 2600 65 130
33 2640 66 132
33.5 2680 67 134
34 2720 68 136
34.5 2760 69 138
35 2800 70 140
Blood volume drawn for the purpose of this study is limited to a maximum of 2.5% of the circulating 
blood volume per sampling session and to a maximum of 5% over a 4 -week period ( Howie 2011 ).
Investigators may  further limit the volume of blood withdrawn based on local institutional guidelines 
and if the clinical condition of the patient may be adversely affected by removal of the blood volumes 
stated above. Details about blood volume requirement for safety  samples are provide in the laboratory 
manual. 
1 For bod y weights >35 kg, use the following formulas to calculate 2.5% and 5% of total blood volume:
2.5% of total blood volume = body weight (in kg to the closest 0.5 kg) X 2

Novartis Confidential Page 79
Amended Clinical Trial Protocol Version 02 ( Clean ) Protocol No. CLCZ696B2319E1
2.5% and 5% Blood volume table by weight (up to 35 kg)1
Body 
Weight 
(Kg)Total blood 
volume of the 
patient (mL)Maximum allowable volume 
(mL) in one blood draw 
(= 2.5% of total blood volume 
of the patient)Total maximum volume (mL) 
drawn in a 28 -day period 
( = 5% of total blood volume 
of the patient)
5% of total blood volume = body weight (in kg to the closest 0.5 kg) X 4
